

PRODUCT MONOGRAPH

PrEYLEA[®]

Aflibercept

Single Use Vials for the Treatment of a Single Eye

40 mg/mL Solution for Intravitreal Injection

Ophthalmological / Antineovascularization agent

ATC Code: S01LA05

Manufactured by:
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6

Date of Approval:
May 19, 2017

<http://www.bayer.ca>

Submission Control No: 186851

© 2017, Bayer Inc.
® see www.bayer.ca/tm-mc

TABLE OF CONTENTS

PART I: HEALTH PROFESSIONAL INFORMATION..... 3
SUMMARY PRODUCT INFORMATION 3
DESCRIPTION..... 3
INDICATIONS AND CLINICAL USE..... 3
CONTRAINDICATIONS 3
WARNINGS AND PRECAUTIONS 4
ADVERSE REACTIONS 7
DRUG INTERACTIONS 31
DOSAGE AND ADMINISTRATION 31
OVERDOSAGE..... 36
ACTION AND CLINICAL PHARMACOLOGY 36
STORAGE AND STABILITY 38
SPECIAL HANDLING INSTRUCTIONS 38
DOSAGE FORMS, COMPOSITION AND PACKAGING 39

PART II: SCIENTIFIC INFORMATION..... 40
PHARMACEUTICAL INFORMATION..... 40
CLINICAL TRIALS 41
DETAILED PHARMACOLOGY 59
TOXICOLOGY 59
REFERENCES..... 61

PART III: CONSUMER INFORMATION 63

PrEYLEA®

Aflibercept, Solution for Intravitreal Injection

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Table 1 – Product Information Summary

Route of Administration	Dosage Form, Strength	Clinically Relevant Non-medicinal Ingredients
Intravitreal Injection	Solution / 40 mg/mL	None <i>For a complete listing see DOSAGE FORMS, COMPOSITION AND PACKAGING section.</i>

DESCRIPTION

EYLEA (aflibercept, solution for intravitreal injection) is a recombinant fusion protein consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.

INDICATIONS AND CLINICAL USE

EYLEA (aflibercept, solution for intravitreal injection) is indicated for:

- the treatment of neovascular (wet) age-related macular degeneration (AMD)
- the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)
- the treatment of visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO)
- the treatment of diabetic macular edema (DME)
- the treatment of myopic choroidal neovascularization (myopic CNV)

CONTRAINDICATIONS

- Patients who are hypersensitive to this drug, to any ingredient in the formulation, or to any component of the container. For a complete listing, see the **DOSAGE FORMS, COMPOSITION AND PACKAGING** section.
- Ocular or periocular infection
- Active intraocular inflammation

WARNINGS AND PRECAUTIONS

Cardiovascular

Thromboembolic Events

Arterial thromboembolic events (ATEs) are adverse events potentially related to systemic VEGF inhibition. There is a potential risk of ATEs following intravitreal use of VEGF inhibitors, including EYLEA.

ATEs, as defined by the Antiplatelet Trialists' Collaboration (APTC) criteria, include nonfatal myocardial infarction, nonfatal stroke, or vascular death (including deaths of unknown cause). The incidence in the VIEW1 and VIEW2 wet AMD studies during the 96 weeks study duration was 3.3% (60 out of 1824) in the combined group of patients treated with EYLEA compared with 3.2% (19 out of 595) in patients treated with ranibizumab.

The incidence of APTC ATEs in the CRVO studies (GALILEO and COPERNICUS) during the 76/100 weeks study duration was 0.9% (2 out of 218) in patients treated with EYLEA+PRN compared to 1.4% (2 out of 142) in the group of patients receiving only sham treatment.

The incidence of APTC ATEs in the BRVO study (VIBRANT) during the 52 weeks study duration was 0% in the EYLEA treatment group patients and 2.2% (2 out of 92) in the laser + EYLEA control group through week 52. One of these patients in the laser group had received EYLEA rescue treatment.

The incidence of ATEs, as defined by APTC criteria in the DME studies (VISTA^{DME} and VIVID^{DME}) during the 52 weeks study duration was 3.3% (19 out of 578) in the combined group of patients treated with EYLEA compared with 2.8% (8 out of 287) in the control group.

The incidence of APTC ATEs in the myopic CNV study (MYRROR) during the 48 weeks study duration was 1.1% (1 out of 91) in the group of patients treated with EYLEA compared to 0% (0 out of 31) in the group of patients in the control group (see [PART II: SCIENTIFIC INFORMATION – CLINICAL TRIALS](#)).

Hepatic/Biliary/Pancreatic

EYLEA has not been studied in patients with hepatic impairment.

Immunogenicity

As with all therapeutic proteins, there is a potential for immunogenicity with EYLEA, and a risk of hypersensitivity reactions including anaphylaxis. Patients should be instructed to report any symptoms of intraocular inflammation, e.g., pain, photophobia, or redness, which, although non-specific, should also be assessed as potential hypersensitivity reactions.

Immunogenicity was measured in serum samples. The immunogenicity data reflect the percentage of patients whose test results were considered positive for antibodies to EYLEA in immunoassays, and are highly dependent on the sensitivity and specificity of the assays.

In Phase III studies, the pre-treatment incidence of immune reactivity to EYLEA was approximately 1% to 3% in all treatment groups. After dosing with EYLEA for up to 96 weeks (wet AMD), 52 weeks (CRVO, BRVO and DME), and 48 weeks (myopic CNV), antibodies to

EYLEA were detected in a similar percentage range of patients. In the wet AMD, CRVO, BRVO, DME, and myopic CNV studies, there were no differences in efficacy or safety between patients with or without immune reactivity.

Ophthalmologic

Endophthalmitis, Retinal detachments and Cataracts

Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis, retinal detachment, retinal tear, retinal pigment epithelium tear, and cataract including traumatic cataract (see **ADVERSE REACTIONS**). The proper aseptic injection technique must always be used when administering EYLEA (see **DOSAGE AND ADMINISTRATION – Administration**). Patients should be instructed to report any symptoms suggestive of any event listed above without delay and should be managed appropriately.

Increase in Intraocular Pressure

Increases in intraocular pressure have been observed within 60 minutes of an intravitreal injection, including with EYLEA (see **ADVERSE REACTIONS**). EYLEA has not been tested in patients with poorly controlled glaucoma. Sustained (present at 2 or more consecutive visits) IOP increases > 21 mm Hg have also been reported in 34 (1.9%) patients treated with EYLEA and 30 (5.0%) patients treated with ranibizumab in wet AMD clinical trials, and in 5 (2.3%) patients treated with EYLEA and 9 (6.3%) patients treated with sham in CRVO clinical trials; and in 7 (7.7%) patients treated with EYLEA and 4 (4.3%) patients treated with laser in the BRVO clinical trial. In the DME Phase III clinical trials, sustained intraocular pressure increases have been reported in 3.6% (21/578) of patients initiated treatment with EYLEA and in 2.4% (7/287) of patients initiated treatment with laser. In all cases, both intraocular pressure and the perfusion of the optic nerve head must therefore be monitored and managed appropriately.

Other

As with other intravitreal anti-VEGF treatments, treatment should be withheld and resumed only when considered appropriate in cases of:

- An IOP of ≥ 30 mmHg
- Within the previous or next 28 days in the event of a performed or planned intraocular surgery
- A retinal break. The treatment should not be resumed until the break is adequately repaired

There is only limited experience in the treatment of subjects with DME due to type I diabetes or in diabetic patients with an HbA1c over 12% or with proliferative diabetic retinopathy.

EYLEA has not been studied in patients with active systemic infections or in patients with concurrent eye conditions such as retinal detachment or macular hole. There is also no experience of treatment with EYLEA in diabetic patients with uncontrolled hypertension. This lack of information should be considered by the physician when treating such patients.

In myopic CNV, a clinical trial was conducted in Japan, South Korea, Singapore, Taiwan and Hong Kong. Thus there is no clinical trial experience with EYLEA in the treatment of non-Asian patients for this indication. Furthermore, there is also no clinical trial experience in patients who have previously undergone treatment for myopic CNV, and in the patients with extrafoveal lesions. This lack of information should be considered by the physician before treating such patients.

Renal

EYLEA has not been studied in patients with renal impairment (see **DOSAGE AND ADMINISTRATION – Recommended Dose and Dosage Adjustment** and **ACTION AND CLINICAL PHARMACOLOGY – Renal Insufficiency**).

Special Populations

Pregnant Women

There are no data on the use of aflibercept in pregnant women. Studies in animals have shown reproductive toxicity after systemic administration including fetal loss and severe embryofetal malformations (see **TOXICOLOGY – Reproductive Toxicology**). EYLEA should not be used during pregnancy unless clearly indicated by medical need, and the potential benefit outweighs the potential risk to the fetus.

Women of Childbearing Potential

Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of EYLEA.

Nursing Women

It is not known whether aflibercept is excreted in human milk. A risk to the breast-fed child cannot be excluded. EYLEA is not recommended during breast-feeding. A decision must be made whether to discontinue breast-feeding or to postpone, if feasible, therapy with EYLEA. The benefits of therapy should be weighed against potential risks to the child.

Pediatric Use (< 18 years of age)

The safety and effectiveness of EYLEA in pediatric patients have not been established.

Geriatric Use

In the wet AMD Phase III clinical trials, 89% (1616/1817) of patients randomized to treatment with EYLEA were ≥ 65 years of age and 63% (1139/1817) were ≥ 75 years of age.

In CRVO studies, approximately 52% (112/217) of the patients randomized to treatment with EYLEA were ≥ 65 years of age, and approximately 18% (38/217) were ≥ 75 years of age.

In the BRVO study, approximately 58% (53/91) of the patients randomized to treatment with EYLEA were 65 years of age or older, and approximately 23% (21/91) were 75 years of age or older.

In the DME Phase III studies, approximately 47% (268/576) of the patients randomized to treatment with EYLEA were ≥ 65 years of age, and approximately 9% (52/576) were ≥ 75 years of age.

In the myopic CNV study, approximately 36% (33/91) of the patients randomized to treatment with EYLEA were ≥ 65 years of age, and approximately 10% (9/91) were ≥ 75 years of age.

No clinically significant differences in efficacy or safety were seen with increasing age in these studies.

Other

In clinical trials, only one eye per patient was treated with EYLEA. The safety and efficacy of EYLEA therapy administered to both eyes concurrently or consecutively have not been studied.

Effects on Ability to Drive and Use Machines

Patients may experience temporary visual disturbances after an intravitreal injection with EYLEA and the associated eye examinations. They should not drive or use machines until visual function has recovered sufficiently.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Treatment of wet AMD

A total of 1824 patients with up to 96 weeks exposure to EYLEA constituted the safety population in the 2 double-blind active-controlled clinical studies (VIEW1 and VIEW2); of these, 1223 patients were treated with the 2 mg dose (see **PART II: SCIENTIFIC INFORMATION - CLINICAL TRIALS**).

Serious adverse reactions related to the injection procedure in the Phase III AMD trials have occurred in less than 1 in 1000 intravitreal injections (22 of 36206 injections) with either EYLEA or ranibizumab, and included endophthalmitis, cataract traumatic, increased intraocular pressure, retinal detachment, and vitreous detachment (see **WARNINGS AND PRECAUTIONS**).

In patients randomized to the EYLEA 2mg every 8 weeks (2Q8) treatment group, fewer injection-related SAEs were observed in comparison to patients treated with EYLEA 2mg every 4 weeks and patients treated with ranibizumab 0.5 mg every 4 weeks (3 [0.5%] vs. 8 [1.3%] vs. 12 [2.0%]). The most common ocular serious adverse events in patients treated with EYLEA 2 mg every 8 weeks and ranibizumab 0.5 mg every 4 weeks, respectively, included: visual acuity reduced (7 [1.1%] vs. 7 [1.2%]), retinal hemorrhage (6 [1.0%] vs. 6 [1.0%]), cataract (4 [0.7%] vs. 5 [0.8%]), retinal pigment epithelial tear (3 [0.5%] vs. 1 [0.2%]) and endophthalmitis (0 [0.0%] vs. 6 [1.0%]).

The most common adverse reactions (in at least 5% of patients treated with EYLEA) were conjunctival hemorrhage (26.7%), eye pain (10.3%), vitreous detachment (8.4%), cataract (7.9%), vitreous floaters (7.6%), and increased intraocular pressure (7.2%). These adverse reactions occurred with a similar incidence in the ranibizumab treatment group.

Treatment of CRVO

Serious adverse reactions related to the injection procedure occurred in 3 out of 2,728 intravitreal injections with EYLEA and included endophthalmitis (see **WARNINGS AND PRECAUTIONS – Endophthalmitis, Retinal detachments and Cataract**), cataract and vitreous detachment.

In CRVO clinical trials, the SAEs which occurred in ≥ 2 patients and occurred more frequently in the EYLEA+PRN group than in the Sham+PRN group in at least one clinical trial were (EYLEA+PRN vs. Sham+PRN): cataract (4 [2%] vs. 1 [1%]), macular edema (5 [2%] vs. 2 [1%]) and cystoid macular edema (2 [1%] vs. 0 [0%]) through week 76/100. The following ocular SAEs each occurred only in one patient receiving EYLEA treatment (1 [0.5%] subject), and in no patients who received sham treatment: endophthalmitis, corneal abrasion, vitreous detachment, retinal artery occlusion, and macular ischemia.

Through week 24, the most common ocular AEs ($\geq 5\%$ of patients treated with EYLEA and more frequently in the EYLEA group than in the Sham group) were (EYLEA vs. Sham): eye pain (13% vs. 5%), conjunctival hemorrhage (12% vs. 11%), intraocular pressure increased (8% vs. 6%), retinal exudates (6% vs. 4%), optic disc vascular disorders (6% vs. 3%) and vitreous floaters (5% vs. 1%). The most common non-ocular AE ($\geq 5\%$ of patients) that occurred more frequently in the EYLEA group than in the Sham group was hypertension (6% vs. 5%).

Through week 76/100, the most common AEs occurred more frequently in the EYLEA+PRN group than in the Sham+PRN group in at least one clinical trial were (EYLEA+PRN vs. Sham+PRN): macular edema (29% vs. 11%), cystoid macular edema (10% vs. 4%), vitreous floaters (7% vs. 4%), ocular hyperemia (7% vs. 4%), visual impairment (4% vs. 1%) and macular degeneration (4% vs. 1%).

Treatment of BRVO

Serious adverse reactions related to the injection procedure occurred in 1 out of 1,115 intravitreal injections with EYLEA: one case of traumatic cataract (see **WARNINGS AND PRECAUTIONS**).

In the BRVO trial, one ocular SAE (traumatic cataract) was observed in the EYLEA group. The overall incidence of SAEs was 10% in the laser group and 10% in the EYLEA by week 24, 11% in the laser group and 15% in the EYLEA group by week 52. No drug-related SAEs were reported. After week 24, patients in the laser group could become eligible for EYLEA treatment.

The most common ocular AEs ($\geq 5\%$) in the study eye were conjunctival hemorrhage (4% laser group and 20% EYLEA group through week 24, 15% laser group and 24% EYLEA group through week 52) and eye pain (5% laser group and 4% EYLEA group through week 24, 8% laser group and 5% EYLEA group through week 52, and eye irritation (1% laser group and 8% EYLEA group through week 52).

Treatment of DME

In the DME Phase III studies, one serious adverse reaction related to the injection procedure (retinal detachment) had occurred in 5940 intravitreal injections (see **WARNINGS AND PRECAUTIONS – Ophthalmologic**).

Ocular serious adverse reactions in patients treated with EYLEA (2Q4 and 2Q8 treatment arms) and laser therapy, respectively, were: cataract (3 [0.5%] vs. 1 [0.3%]); increased intraocular pressure (1 [0.2%] vs. 0 [0.0%]); and retinal detachment (1 [0.2%] vs. 0 [0.0%]).

The most common adverse reactions (in at least 5% of patients randomized to the EYLEA treatment arms (2Q4 and 2Q8) were conjunctival hemorrhage (28.0%), eye pain (9.0%), cataract (5.0%) and vitreous floaters (5.9%).

Treatment of myopic CNV

In the myopic CNV Phase III study (MYRROR), one serious adverse reaction related to the injection procedure (macular hole) had occurred in 474 intravitreal injections with EYLEA.

One ocular serious adverse reaction (macular hole) occurred in patients treated with EYLEA.

The most common adverse reactions (in at least 5% of patients randomized to the EYLEA arm were: conjunctival hemorrhage (11.0%), eye pain (7.7%), punctate keratitis (6.6%).

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Treatment of wet AMD

The safety data include all adverse drug reactions (serious and non-serious) with a reasonable possibility of causality to the injection procedure or medicinal product (see [Table 2](#) for baseline to week 52 data and [Table 3](#) for week 52 to week 96 data).

Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in either EYLEA treatment arms), with a difference of $\geq 2\%$ between EYLEA and ranibizumab in at least one study (from baseline to week 96 data) are presented in [Table 4](#).

**Table 2: Adverse Drug Reactions (Ocular and Non-Ocular) VIEW1 and VIEW2 wet AMD Studies
Adverse Reactions Possibly Related to EYLEA with Incidence rate ≥1% (52 week data; safety population)**

Primary system organ class Preferred term MedDRA Version 16.0	VIEW1			VIEW2		
	Ranibizumab 0.5 mg Q4 N=304 (100%)	EYLEA 2.0 mg Q4 N=304 (100%)	EYLEA 2.0 mg Q8 N=303 (100%)	Ranibizumab 0.5 mg Q4 N=291 (100%)	EYLEA 2.0 mg Q4 N=309 (100%)	EYLEA 2.0 mg Q8 N=307 (100%)
Eye disorders						
Anterior chamber flare	3 (1.0%)	0	3 (1.0%)	4 (1.4%)	2 (0.6%)	1 (0.3%)
Cataract	6 (2.0%)	11 (3.6%)	8 (2.6%)	15 (5.2%)	16 (5.2%)	12 (3.9%)
Cataract cortical	2 (0.7%)	2 (0.7%)	4 (1.3%)	1 (0.3%)	0	2 (0.7%)
Cataract nuclear	7 (2.3%)	4 (1.3%)	6 (2.0%)	4 (1.4%)	5 (1.6%)	1 (0.3%)
Cataract subcapsular	2 (0.7%)	2 (0.7%)	6 (2.0%)	1 (0.3%)	3 (1.0%)	2 (0.7%)
Conjunctival hemorrhage	144 (47.4%)	109 (35.9%)	131 (43.2%)	24 (8.2%)	25 (8.1%)	29 (9.4%)
Conjunctival hyperemia	4 (1.3%)	2 (0.7%)	2 (0.7%)	14 (4.8%)	6 (1.9%)	1 (0.3%)
Corneal epithelium defect	2 (0.7%)	1 (0.3%)	0	2 (0.7%)	4 (1.3%)	3 (1.0%)
Corneal erosion	0	0	0	7 (2.4%)	3 (1.0%)	7 (2.3%)
Corneal edema	3 (1.0%)	4 (1.3%)	4 (1.3%)	0	5 (1.6%)	2 (0.7%)
Detachment of retinal pigment epithelium	6 (2.0%)	5 (1.6%)	4 (1.3%)	14 (4.8%)	19 (6.1%)	12 (3.9%)
Eye pain	26 (8.6%)	33 (10.9%)	22 (7.3%)	27 (9.3%)	33 (10.7%)	21 (6.8%)
Eyelid edema	5 (1.6%)	2 (0.7%)	3 (1.0%)	7 (2.4%)	7 (2.3%)	4 (1.3%)
Foreign body sensation in eyes	9 (3.0%)	8 (2.6%)	16 (5.3%)	13 (4.5%)	13 (4.2%)	5 (1.6%)
Lacrimation increased	6 (2.0%)	9 (3.0%)	11 (3.6%)	2 (0.7%)	7 (2.3%)	5 (1.6%)
Ocular hyperemia	11 (3.6%)	8 (2.6%)	3 (1.0%)	18 (6.2%)	13 (4.2%)	8 (2.6%)
Retinal detachment	5 (1.6%)	4 (1.3%)	11 (3.6%)	5 (1.7%)	4 (1.3%)	11 (3.6%)
Retinal pigment epithelial tear	5 (1.6%)	1 (0.3%)	11 (3.6%)	2 (0.7%)	2 (0.6%)	7 (2.3%)
Vision blurred	10 (3.3%)	11 (3.6%)	8 (2.6%)	2 (0.7%)	4 (1.3%)	3 (1.0%)
Vitreous detachment	24 (7.9%)	26 (8.6%)	21 (6.9%)	9 (3.1%)	20 (6.5%)	15 (4.9%)
Vitreous floaters	33 (10.9%)	40 (13.2%)	20 (6.6%)	10 (3.4%)	10 (3.2%)	8 (2.6%)
General disorders and administration site conditions						
Injection site hemorrhage	5 (1.6%)	6 (2.0%)	6 (2.0%)	5 (1.7%)	5 (1.6%)	4 (1.3%)
Injection site irritation	2 (0.7%)	0	4 (1.3%)	0	0	0
Injection site pain	11 (3.6%)	9 (3.0%)	12 (4.0%)	9 (3.1%)	11 (3.6%)	8 (2.6%)
Infections and infestations						
Endophthalmitis	3 (1.0%)	3 (1.0%)	0	0	0	0
Injury, poisoning and procedural complications						
Corneal abrasion	4 (1.3%)	3 (1.0%)	4 (1.3%)	1 (0.3%)	2 (0.6%)	1 (0.3%)

**Table 2: Adverse Drug Reactions (Ocular and Non-Ocular) VIEW1 and VIEW2 wet AMD Studies
Adverse Reactions Possibly Related to EYLEA with Incidence rate ≥1% (52 week data; safety population)**

Primary system organ class Preferred term MedDRA Version 16.0	VIEW1			VIEW2		
	Ranibizumab 0.5 mg Q4 N=304 (100%)	EYLEA 2.0 mg Q4 N=304 (100%)	EYLEA 2.0 mg Q8 N=303 (100%)	Ranibizumab 0.5 mg Q4 N=291 (100%)	EYLEA 2.0 mg Q4 N=309 (100%)	EYLEA 2.0 mg Q8 N=307 (100%)
Investigations						
Intraocular pressure increased	21 (6.9%)	14 (4.6%)	15 (5.0%)	20 (6.9%)	24 (7.8%)	16 (5.2%)

Note: Patients are only counted once in each row but may appear in more than one row.

**Table 3: Adverse Drug Reactions (Ocular and Non-Ocular) VIEW1 and VIEW2 wet AMD Studies
Adverse Reactions Possibly Related to EYLEA with Incidence rate ≥1% (from week 52 to week 96 data^a; safety population)**

Primary system organ class Preferred term MedDRA Version 16.0	VIEW1			VIEW2		EYLEA 2.0 mg Q8 N=284 (100%)
	Ranibizumab 0.5 mg Q4 N=280 (100%)	EYLEA 2.0 mg Q4 N=290 (100%)	EYLEA 2.0 mg Q8 N=274 (100%)	Ranibizumab 0.5 mg Q4 N=276 (100%)	EYLEA 2.0 mg Q4 N=281 (100%)	
Eye Disorders						
Cataract	7 (2.5%)	12 (4.1%)	5 (1.8%)	13 (4.7%)	15 (5.3%)	18 (6.3%)
Cataract cortical	3 (1.1%)	1 (0.3%)	3 (1.1%)	1 (0.4%)	1 (0.4%)	2 (0.7%)
Cataract nuclear	2 (0.7%)	4 (1.4%)	4 (1.5%)	2 (0.7%)	5 (1.8%)	1 (0.4%)
Cataract subcapsular	2 (0.7%)	4 (1.4%)	3 (1.1%)	0	2 (0.7%)	2 (0.7%)
Conjunctival hemorrhage	52 (18.6%)	37 (12.8%)	41 (15.0%)	9 (3.3%)	4 (1.4%)	3 (1.1%)
Conjunctival hyperemia	6 (2.1%)	0	1 (0.4%)	6 (2.2%)	2 (0.7%)	3 (1.1%)
Corneal edema	1 (0.4%)	2 (0.7%)	3 (1.1%)	0	3 (1.1%)	0
Detachment of retinal pigment epithelium	1 (0.4%)	2 (0.7%)	8 (2.9%)	7 (2.5%)	3 (1.1%)	4 (1.4%)
Eye pain	11 (3.9%)	12 (4.1%)	11 (4.0%)	2 (0.7%)	6 (2.1%)	6 (2.1%)
Eyelid edema	2 (0.7%)	0	4 (1.5%)	1 (0.4%)	0	1 (0.4%)
Foreign body sensation in eyes	4 (1.4%)	4 (1.4%)	8 (2.9%)	1 (0.4%)	1 (0.4%)	2 (0.7%)
Lacrimation increased	5 (1.8%)	3 (1.0%)	6 (2.2%)	0	5 (1.8%)	4 (1.4%)
Ocular hyperemia	2 (0.7%)	0	2 (0.7%)	2 (0.7%)	5 (1.8%)	1 (0.4%)
Punctate keratitis	2 (0.7%)	3 (1.0%)	4 (1.5%)	3 (1.1%)	1 (0.4%)	2 (0.7%)
Retinal detachment	0	1 (0.3%)	0	1 (0.4%)	2 (0.7%)	5 (1.8%)
Vision blurred	4 (1.4%)	8 (2.8%)	7 (2.6%)	3 (1.1%)	2 (0.7%)	2 (0.7%)
Vitreous detachment	9 (3.2%)	10 (3.4%)	7 (2.6%)	7 (2.5%)	6 (2.1%)	4 (1.4%)
Vitreous floaters	16 (5.7%)	13 (4.5%)	12 (4.4%)	1 (0.4%)	0	3 (1.1%)
Investigations						
Intraocular pressure increased	15 (5.4%)	4 (1.4%)	8 (2.9%)	18 (6.5%)	13 (4.6%)	15 (5.3%)

a During this period (weeks 52 to 96), patients continued to receive the dosage strength to which they were initially randomized but on a modified dosing schedule guided by assessment of visual and anatomic outcomes with a protocol-defined maximum dosing interval of 12 weeks

Note: Patients are only counted once in each row but may appear in more than one row.

Table 4: Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in either EYLEA treatment arms), with a difference of $\geq 2\%$ between EYLEA and ranibizumab in at least one study (from baseline to week 96 data; safety population; VIEW1 and VIEW2 Studies)

Primary system organ class Preferred term MedDRA Version 14.0	VIEW1			VIEW2		
	Ranibizumab 0.5 mg Q4 N=304 (100%)	EYLEA 2.0 mg Q4 N=304 (100%)	EYLEA 2.0 mg Q8 N=303 (100%)	Ranibizumab 0.5 mg Q4 N=291 (100%)	EYLEA 2.0 mg Q4 N=309 (100%)	EYLEA 2.0 mg Q8 N=307 (100%)
Eye disorders						
Blepharitis	15 (4.9%)	17 (5.6%)	15 (5.0%)	12 (4.1%)	9 (2.9%)	6 (2.0%)
Choroidal neovascularization	1 (0.3%)	1 (0.3%)	0	14 (4.8%)	4 (1.3%)	5 (1.6%)
Conjunctival hemorrhage	147 (48.4%)	117 (38.5%)	140 (46.2%)	31 (10.7%)	28 (9.1%)	31 (10.1%)
Conjunctival hyperaemia	9 (3.0%)	2 (0.7%)	3 (1.0%)	16 (5.5%)	7 (2.3%)	4 (1.3%)
Conjunctivitis	3 (1.0%)	0	1 (0.3%)	15 (5.2%)	8 (2.6%)	17 (5.5%)
Corneal edema	4 (1.3%)	6 (2.0%)	5 (1.7%)	0	7 (2.3%)	2 (0.7%)
Corneal erosion	1 (0.3%)	0	0	9 (3.1%)	3 (1.0%)	9 (2.9%)
Eye irritation	19 (6.3%)	13 (4.3%)	16 (5.3%)	4 (1.4%)	5 (1.6%)	4 (1.3%)
Eye pain	34 (11.2%)	39 (12.8%)	31 (10.2%)	28 (9.6%)	35 (11.3%)	23 (7.5%)
Foreign body sensation in eyes	9 (3.0%)	10 (3.3%)	19 (6.3%)	14 (4.8%)	13 (4.2%)	7 (2.3%)
Lacrimation increased	11 (3.6%)	11 (3.6%)	16 (5.3%)	2 (0.7%)	12 (3.9%)	7 (2.3%)
Macular degeneration	18 (5.9%)	22 (7.2%)	16 (5.3%)	31 (10.7%)	32 (10.4%)	41 (13.4%)
Macular edema	13 (4.3%)	4 (1.3%)	3 (1.0%)	11 (3.8%)	8 (2.6%)	15 (4.9%)
Maculopathy	22 (7.2%)	10 (3.3%)	11 (3.6%)	10 (3.4%)	13 (4.2%)	8 (2.6%)
Ocular discomfort	10 (3.3%)	7 (2.3%)	4 (1.3%)	0	1 (0.3%)	0
Ocular hyperaemia	12 (3.9%)	8 (2.6%)	5 (1.7%)	19 (6.5%)	16 (5.2%)	9 (2.9%)
Posterior capsule opacification	4 (1.3%)	8 (2.6%)	12 (4.0%)	7 (2.4%)	6 (1.9%)	3 (1.0%)
Punctate keratitis	6 (2.0%)	10 (3.3%)	6 (2.0%)	10 (3.4%)	4 (1.3%)	7 (2.3%)
Retinal degeneration	9 (3.0%)	10 (3.3%)	13 (4.3%)	18 (6.2%)	22 (7.1%)	10 (3.3%)
Retinal edema	13 (4.3%)	10 (3.3%)	25 (8.3%)	10 (3.4%)	11 (3.6%)	17 (5.5%)
Retinal hemorrhage	33 (10.9%)	30 (9.9%)	43 (14.2%)	52 (17.9%)	55 (17.8%)	56 (18.2%)
Vision blurred	12 (3.9%)	18 (5.9%)	13 (4.3%)	5 (1.7%)	6 (1.9%)	4 (1.3%)
Visual acuity reduced	33 (10.9%)	37 (12.2%)	32 (10.6%)	34 (11.7%)	39 (12.6%)	47 (15.3%)
Vitreous cells	7 (2.3%)	4 (1.3%)	1 (0.3%)	2 (0.7%)	2 (0.6%)	3 (1.0%)
Vitreous detachment	33 (10.9%)	35 (11.5%)	28 (9.2%)	15 (5.2%)	26 (8.4%)	19 (6.2%)
Vitreous floaters	47 (15.5%)	49 (16.1%)	29 (9.6%)	11 (3.8%)	10 (3.2%)	10 (3.3%)

Table 4: Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in either EYLEA treatment arms), with a difference of $\geq 2\%$ between EYLEA and ranibizumab in at least one study (from baseline to week 96 data; safety population; VIEW1 and VIEW2 Studies)

Primary system organ class Preferred term MedDRA Version 14.0	VIEW1			VIEW2		
	Ranibizumab 0.5 mg Q4 N=304 (100%)	EYLEA 2.0 mg Q4 N=304 (100%)	EYLEA 2.0 mg Q8 N=303 (100%)	Ranibizumab 0.5 mg Q4 N=291 (100%)	EYLEA 2.0 mg Q4 N=309 (100%)	EYLEA 2.0 mg Q8 N=307 (100%)
Cardiac disorders						
Atrial fibrillation	15 (4.9%)	8 (2.6%)	18 (5.9%)	4 (1.4%)	10 (3.2%)	7 (2.3%)
Atrioventricular block first degree	16 (5.3%)	18 (5.9%)	9 (3.0%)	14 (4.8%)	23 (7.4%)	13 (4.2%)
Bundle branch block left	6 (2.0%)	13 (4.3%)	4 (1.3%)	7 (2.4%)	5 (1.6%)	4 (1.3%)
Myocardial infarction	8 (2.6%)	1 (0.3%)	4 (1.3%)	6 (2.1%)	3 (1.0%)	4 (1.3%)
Ear and labyrinth disorders						
Vertigo	4 (1.3%)	6 (2.0%)	10 (3.3%)	3 (1.0%)	4 (1.3%)	5 (1.6%)
Gastrointestinal disorders						
Diarrhea	18 (5.9%)	18 (5.9%)	9 (3.0%)	14 (4.8%)	9 (2.9%)	16 (5.2%)
Gastritis	0	2 (0.7%)	1 (0.3%)	0	3 (1.0%)	7 (2.3%)
Gastroesophageal reflux disease	12 (3.9%)	4 (1.3%)	10 (3.3%)	4 (1.4%)	5 (1.6%)	6 (2.0%)
General disorders and administration site conditions						
Fatigue	5 (1.6%)	5 (1.6%)	8 (2.6%)	0	1 (0.3%)	6 (2.0%)
Pyrexia	5 (1.6%)	5 (1.6%)	6 (2.0%)	18 (6.2%)	14 (4.5%)	9 (2.9%)
Immune system disorders						
Seasonal allergy	6 (2.0%)	11 (3.6%)	15 (5.0%)	0	1 (0.3%)	4 (1.3%)
Infections and infestations						
Influenza	15 (4.9%)	11 (3.6%)	14 (4.6%)	13 (4.5%)	19 (6.1%)	23 (7.5%)
Nasopharyngitis	36 (11.8%)	45 (15.1%)	39 (12.9%)	38 (13.1%)	24 (7.8%)	26 (8.5%)
Pneumonia	24 (7.9%)	10 (3.3%)	14 (4.6%)	2 (0.7%)	10 (3.2%)	6 (2.0%)
Tooth infection	7 (2.3%)	1 (0.3%)	1 (0.3%)	2 (0.7%)	1 (0.3%)	2 (0.7%)
Upper respiratory tract infection	18 (5.9%)	18 (5.9%)	26 (8.6%)	8 (2.7%)	4 (1.3%)	7 (2.3%)
Injury, poisoning and procedural complications						
Fall	26 (8.6%)	24 (7.9%)	35 (11.6%)	11 (3.8%)	10 (3.2%)	7 (2.3%)
Investigations						
Intraocular pressure increased	32 (10.5%)	16 (5.3%)	21 (6.9%)	32 (11.0%)	32 (10.4%)	26 (8.5%)
Blood glucose increased	13 (4.3%)	13 (4.3%)	16 (5.3%)	7 (2.4%)	16 (5.2%)	15 (4.9%)
Blood pressure diastolic increased	2 (0.7%)	0	0	11 (3.8%)	4 (1.3%)	1 (0.3%)
Urine protein / creatinine ratio increased	8 (2.6%)	14 (4.6%)	11 (3.6%)	5 (1.7%)	2 (0.6%)	4 (1.3%)

Table 4: Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in either EYLEA treatment arms), with a difference of $\geq 2\%$ between EYLEA and ranibizumab in at least one study (from baseline to week 96 data; safety population; VIEW1 and VIEW2 Studies)

Primary system organ class Preferred term MedDRA Version 14.0	VIEW1			VIEW2		
	Ranibizumab 0.5 mg Q4 N=304 (100%)	EYLEA 2.0 mg Q4 N=304 (100%)	EYLEA 2.0 mg Q8 N=303 (100%)	Ranibizumab 0.5 mg Q4 N=291 (100%)	EYLEA 2.0 mg Q4 N=309 (100%)	EYLEA 2.0 mg Q8 N=307 (100%)
Metabolism and nutrition disorders						
Diabetes mellitus	8 (2.6%)	5 (1.6%)	1 (0.3%)	9 (3.1%)	9 (2.9%)	10 (3.3%)
Musculoskeletal and connective tissue disorders						
Arthralgia	17 (5.6%)	18 (5.9%)	8 (2.6%)	11 (3.8%)	9 (2.9%)	7 (2.3%)
Muscle spasms	10 (3.3%)	3 (1.0%)	7 (2.3%)	4 (1.4%)	3 (1.0%)	3 (1.0%)
Osteoarthritis	9 (3.0%)	2 (0.7%)	11 (3.6%)	5 (1.7%)	9 (2.9%)	9 (2.9%)
Pain in extremity	2 (0.7%)	11 (3.6%)	7 (2.3%)	8 (2.7%)	5 (1.6%)	5 (1.6%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)						
Basal cell carcinoma	5 (1.6%)	11 (3.6%)	17 (5.6%)	3 (1.0%)	0	0
Nervous system disorders						
Dizziness	8 (2.6%)	10 (3.3%)	10 (3.3%)	15 (5.2%)	8 (2.6%)	5 (1.6%)
Headache	21 (6.9%)	14 (4.6%)	15 (5.0%)	13 (4.5%)	12 (3.9%)	20 (6.5%)
Psychiatric disorders						
Anxiety	12 (3.9%)	5 (1.6%)	8 (2.6%)	3 (1.0%)	5 (1.6%)	6 (2.0%)
Insomnia	10 (3.3%)	3 (1.0%)	7 (2.3%)	1 (0.3%)	3 (1.0%)	4 (1.3%)
Renal and urinary disorders						
Leukocyturia	0	0	0	7 (2.4%)	5 (1.6%)	1 (0.3%)
Respiratory, thoracic and mediastinal disorders						
Chronic obstructive pulmonary disease	9 (3.0%)	8 (2.6%)	16 (5.3%)	2 (0.7%)	2 (0.6%)	1 (0.3%)
Cough	16 (5.3%)	13 (4.3%)	13 (4.3%)	11 (3.8%)	6 (1.9%)	5 (1.6%)
Oropharyngeal pain	12 (3.9%)	7 (3.0%)	1 (0.3%)	1 (0.3%)	3 (1.0%)	4 (1.3%)
Skin and subcutaneous tissue disorders						
Rash	7 (2.3%)	3 (1.0%)	0	1 (0.3%)	8 (2.6%)	1 (0.3%)
Vascular disorders						
Hypertension	36 (11.8%)	30 (9.9%)	33 (10.9%)	39 (13.4%)	41 (13.3%)	31 (10.1%)

Note: Patients are only counted once in each row but may appear in more than one row.

In addition, 157 wet AMD patients were treated for up to 44 months in a long term extension of the Phase I and Phase II studies. The safety profile was consistent with that seen in the Phase III wet AMD studies.

Treatment of CRVO

A total of 317 patients treated with at least one dose of EYLEA constituted the safety population in the two Phase III CRVO studies (COPERNICUS and GALILEO).

Patients in the EYLEA groups (n=218) received EYLEA 2 mg, monthly for 6 months and then received EYLEA only if they met prespecified treatment criteria to Week 76 (Study GALILEO) or Week 100 (Study COPERNICUS). Patients in the Control groups received sham injections monthly from baseline to Week 24 (Study COPERNICUS, n=74) or to Week 52 (Study GALILEO, n=68) and then received EYLEA if they met prespecified treatment criteria.

The most common adverse drug reactions ($\geq 1\%$) which have been assessed as having reasonable or suspected relationship to either the study drug or the injection procedure in the CRVO studies (COPERNICUS and GALILEO) are presented in [Table 5](#).

Table 5: Adverse Drug Reactions ($\geq 1\%$) in CRVO Studies (up to 76/100 weeks)

Preferred term MedDRA Version 14.1	EYLEA ^a (N=218)	Control ^a (N=142)	EYLEA ^a + PRN (N=218)	Control ^a + PRN (N=142)	EYLEA Total ^b (N= 317)
	Baseline to Week 24		Baseline to Week 76/100		
Conjunctival hemorrhage	11.9%	11.3%	18.3%	14.1%	15.8%
Intraocular pressure increased	7.8%	6.3%	14.7%	12.0%	12.9%
Eye pain	12.8%	4.9%	16.5%	7.7%	12.6%
Vitreous detachment	2.8%	4.2%	9.2%	5.6%	6.9%
Vitreous floaters	5.0%	1.4%	7.3%	3.5%	5.7%
Lacrimation increased	2.8%	3.5%	4.6%	7.0%	5.0%
Ocular hyperemia	4.1%	2.8%	6.9%	2.8%	5.0%
Cataract	0%	0.7%	5.0%	3.5%	4.4%
Foreign body sensation in eyes	3.2%	4.9%	4.1%	5.6%	3.5%
Injection site pain	2.8%	1.4%	4.1%	2.1%	3.2%
Corneal abrasion	1.8%	0.7%	2.8%	1.4%	2.2%
Vision blurred	1.4%	0.7%	2.3%	1.4%	1.9%
Cataract nuclear	0%	0.7%	1.8%	0.7%	1.6%
Injection site hemorrhage	0%	0%	1.4%	1.4%	1.6%
Lenticular opacities	0.9%	0.7%	1.8%	0.7%	1.3%
Corneal erosion	1.4%	0.7%	1.4%	2.1%	1.3%
Retinal tear	0.5%	0.7%	1.4%	1.4%	1.3%

PRN: As needed (*pro re nata*)

a As randomized in the GALILEO or COPERNICUS study

b EYLEA Total = all patients who received at least one active EYLEA injection including patients who were previously in the Control arm.

Note: Patients are only counted once in each row but may appear in more than one row.

Table 6: Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in any treatment arm), with a difference of $\geq 2\%$ between EYLEA and Sham (COPERNICUS and GALILEO Studies, 24 weeks)

Primary system organ class Preferred term MedDRA Version 14.1	EYLEA 2Q4 N=218	Control (Sham Injection) N=142
Eye disorders		
Eye irritation	9 (4.1%)	10 (7.0%)
Eye pain	28 (12.8%)	7 (4.9%)
Iris neovascularisation	2 (0.9%)	7 (4.9%)
Macular degeneration	5 (2.3%)	0
Macular edema	6 (2.8%)	12 (8.5%)
Maculopathy	13 (6.0%)	3 (2.1%)
Optic disc vascular disorder	12 (5.5%)	4 (2.8%)
Retinal exudates	14 (6.4%)	6 (4.2%)
Retinal hemorrhage	10 (4.6%)	11 (7.7%)
Retinal neovascularisation	1 (0.5%)	4 (2.8%)
Retinal vascular disorder	12 (5.5%)	12 (8.5%)
Visual acuity reduced	9 (4.1%)	20 (14.1%)
Vitreous floaters	13 (6.0%)	2 (1.4%)
Vitreous hemorrhage	5 (2.3%)	8 (5.6%)
Gastrointestinal disorders		
Nausea	0	4 (2.8%)
Investigations		
Intraocular pressure increased	18 (8.3%)	9 (6.3%)
Injury, poisoning and procedural complications		
Fall	0	3 (2.1%)
Musculoskeletal and connective tissue disorders		
Arthralgia	2 (0.9%)	6 (4.2%)
Respiratory, thoracic and mediastinal disorders		
Cough	1 (0.5%)	4 (2.8%)

Note: Patients are only counted once in each row but may appear in more than one row.

Table 7: Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in any treatment arm), with a difference of $\geq 2\%$ between EYLEA and Sham in at least one study (COPERNICUS and GALILEO Studies, Week 24 to Week 76/100)

System organ class, Preferred term MedDRA Version 14.1	COPERNICUS		GALILEO			
	Week 24 to Week 100		Week 24 to Week 52		Week 52 to Week 76	
	EYLEA+PRN N=110	SHAM+PRN N=60	EYLEA+PRN N=97	SHAM N=57	EYLEA+PRN N= 91	SHAM+PRN N= 52
Blood and Lymphatic Disorders						
Anemia	5 (4.5%)	2 (3.3%)	0	2 (3.5%)	0	1 (1.9%)
Cardiac Disorders						
Cardiac failure congestive	1 (0.9%)	2 (3.3%)	0	0	0	0
Coronary artery disease	3 (2.7%)	0	0	0	0	1 (1.9%)
Eye Disorders						
Anterior chamber angle neovascularization	0	0	2 (2.1%)	0	1 (1.1%)	0
Blepharitis	3 (2.7%)	0	2 (2.1%)	0	0	1 (1.9%)
Conjunctival hemorrhage	16 (14.5%)	9 (15.0%)	5 (5.2%)	1 (1.8%)	6 (6.6%)	1 (1.9%)
Corneal erosion	0	1 (1.7%)	1 (1.0%)	2 (3.5%)	0	0
Cystoid macular edema	16 (14.5%)	4 (6.7%)	3 (3.1%)	0	4 (4.4%)	1 (1.9%)
Diabetic retinopathy	1 (0.9%)	3 (5.0%)	0	0	0	0
Dry Eye	1 (0.9%)	4 (6.7%)	2 (2.1%)	0	0	1 (1.9%)
Eye irritation	5 (4.5%)	2 (3.3%)	4 (4.1%)	1 (1.8%)	0	2 (3.8%)
Eye pain	10 (9.1%)	5 (8.3%)	6 (6.2%)	2 (3.5%)	1 (1.1%)	0
Foreign body sensation in eyes	1 (0.9%)	2 (3.3%)	2 (2.1%)	0	1 (1.1%)	0
Iris neovascularisation	1 (0.9%)	2 (3.3%)	3 (3.1%)	0	2 (2.2%)	0
Lacrimation increased	4 (3.6%)	4 (6.7%)	3 (3.1%)	4 (7.0%)	1 (1.1%)	2 (3.8%)
Macular cyst	2 (1.8%)	1 (1.7%)	1 (1.0%)	2 (3.5%)	1 (1.1%)	0
Macular degeneration	2 (1.8%)	2 (3.3%)	3 (3.1%)	0	0	0
Macular fibrosis	8 (7.3%)	6 (10.0%)	4 (4.1%)	3 (5.3%)	2 (2.2%)	4 (7.7%)
Macular edema	21 (19.1%)	2 (3.3%)	33 (34.0%)	7 (12.3%)	21 (23.1%)	2 (3.8%)
Maculopathy	6 (5.5%)	2 (3.3%)	1 (1.0%)	0	0	0
Ocular hyperemia	4 (3.6%)	0	2 (2.1%)	1 (1.8%)	4 (4.4%)	1 (1.9%)
Optic disc hemorrhage	3 (2.7%)	0	2 (2.1%)	0	1 (1.1%)	0
Optic disc hyperemia	1 (0.9%)	0	2 (2.1%)	0	0	0
Optic disc vascular disorder	8 (7.3%)	5 (8.3%)	2 (2.1%)	3 (5.3%)	0	0
Posterior capsule opacification	3 (2.7%)	0	0	0	0	1 (1.9%)
Punctate keratitis	2 (1.8%)	3 (5.0%)	1 (1.0%)	0	1 (1.1%)	1 (1.9%)

Table 7: Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in any treatment arm), with a difference of $\geq 2\%$ between EYLEA and Sham in at least one study (COPERNICUS and GALILEO Studies, Week 24 to Week 76/100)

System organ class, Preferred term MedDRA Version 14.1	COPERNICUS		GALILEO			
	Week 24 to Week 100		Week 24 to Week 52		Week 52 to Week 76	
	EYLEA+PRN	SHAM+PRN	EYLEA+PRN	SHAM	EYLEA+PRN	SHAM+PRN
	N=110	N=60	N=97	N=57	N= 91	N= 52
Retinal aneurysm	4 (3.6%)	3 (5.0%)	(%)	(%)	2 (2.2%)	0
Retinal degeneration	3 (2.7%)	4 (6.7%)	3 (3.5%)	2 (3.5%)	0	1 (1.9%)
Retinal exudates	7 (6.4%)	5 (8.3%)	3 (3.1%)	4 (7.0%)	1 (1.1%)	0
Retinal hemorrhage	15 (13.6%)	8 (13.3%)	7 (7.2%)	4 (7.0%)	7 (7.7%)	3 (5.8%)
Retinal ischemia	0	0	3 (3.1%)	3 (5.3%)	1 (1.1%)	0
Retinal edema	3 (2.7%)	0	0	1 (1.8%)	0	0
Retinal pigment epitheliopathy	4 (3.6%)	12 (20.0%)	1 (1.0%)	0	0	2 (3.8%)
Retinal vascular disorder	9 (8.2%)	3 (5.0%)	9 (9.3%)	3 (5.3%)	1 (1.1%)	3 (5.8%)
Retinal vein occlusion	5 (4.5%)	0	5 (5.2%)	0	2 (2.2%)	0
Visual acuity reduced	30 (27.3%)	8 (13.3%)	11 (11.3%)	2 (3.5%)	9 (9.9%)	1 (1.9%)
Visual impairment	2 (1.8%)	0	4 (4.1%)	0	1 (1.1%)	0
Vitreous detachment	8 (7.3%)	3 (5.0%)	2 (2.1%)	0	3 (3.3%)	0
Vitreous hemorrhage	2 (1.8%)	4 (6.7%)	2 (2.1%)	1 (1.8%)	0	1 (1.9%)
Gastrointestinal Disorders						
Abdominal pain	0	2 (3.3%)	0	0	0	0
Constipation	1 (0.9%)	2 (3.3%)	0	0	0	0
Diarrhea	2 (1.8%)	2 (3.3%)	1 (1.0%)	1 (1.8%)	0	2 (3.8%)
Dyspepsia	1 (0.9%)	2 (3.3%)	1 (1.0%)	0	0	0
Dysphagia	0	2 (3.3%)	0	0	0	0
Gastritis	0	2 (3.3%)	0	0	0	0
Nausea	5 (4.5%)	0	0	3 (5.3%)	0	0
Toothache	1 (0.9%)	0	1 (1.0%)	0	2 (2.2%)	0
Vomiting	1 (0.9%)	1 (1.7%)	0	3 (5.3%)	1 (1.1%)	0
General Disorders and Administration Site Conditions						
Pyrexia	2 (1.8%)	3 (5.0%)	0	2 (3.5%)	0	0
Immune System Disorders						
Drug hypersensitivity	0	4 (6.7%)	1 (1.0%)	0	0	0
Seasonal allergy	3 (2.7%)	3 (5.0%)	0	1 (1.8%)	0	0

Table 7: Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in any treatment arm), with a difference of $\geq 2\%$ between EYLEA and Sham in at least one study (COPERNICUS and GALILEO Studies, Week 24 to Week 76/100)

System organ class, Preferred term MedDRA Version 14.1	COPERNICUS		GALILEO			
	Week 24 to Week 100		Week 24 to Week 52		Week 52 to Week 76	
	EYLEA+PRN N=110	SHAM+PRN N=60	EYLEA+PRN N=97	SHAM N=57	EYLEA+PRN N= 91	SHAM+PRN N= 52
Infections and Infestations						
Bronchitis	5 (4.5%)	3 (5.0%)	4 (4.1%)	0	0	1 (1.9%)
Herpes zoster	1 (0.9%)	2 (3.3%)	0	1 (1.8%)	0	0
Influenza	7 (6.4%)	3 (5.0%)	5 (5.2%)	1 (1.8%)	1 (1.1%)	1 (1.9%)
Nasopharyngitis	6 (5.5%)	3 (5.0%)	10 (10.3%)	11 (19.3%)	4 (4.4%)	2 (3.8%)
Pharyngitis	3 (2.7%)	0	0	0	0	0
Pneumonia	3 (2.7%)	5 (8.3%)	1 (1.0%)	1 (1.8%)	0	0
Tooth infection	3 (2.7%)	0	0	0	1 (1.1%)	0
Upper respiratory tract infection	6 (5.5%)	2 (3.3%)	0	0	1 (1.1%)	0
Urinary tract infection	5 (4.5%)	1 (1.7%)	1 (1.0%)	1 (1.8%)	0	0
Injury, Poisoning and Procedural Complications						
Accident	1 (0.9%)	3 (5.0%)	0	0	0	0
Contusion	1 (0.9%)	1 (1.7%)	0	2 (3.5%)	0	1 (1.9%)
Fall	3 (2.7%)	4 (6.7%)	1 (1.0%)	1 (1.8%)	0	0
Investigations						
Blood glucose increased	3 (2.7%)	3 (5.0%)	0	0	0	0
Blood pressure increased	1 (0.9%)	3 (5.0%)	0	0	0	0
Blood pressure systolic increased	1 (0.9%)	4 (6.7%)	0	0	0	0
Blood urine present	2 (1.8%)	4 (6.7%)	0	0	0	0
Glucose urine present	2 (1.8%)	3 (5.0%)	0	0	0	0
Intraocular pressure increased	10 (9.1%)	11 (18.3%)	13 (13.4%)	2 (3.5%)	0	0
Lymphocyte count decreased	1 (0.9%)	2 (3.3%)	0	0	0	0
Protein urine present	4 (3.6%)	5 (8.3%)	0	1 (1.8%)	0	0
Visual acuity tests abnormal	4 (3.6%)	2 (3.3%)	5 (5.2%)	0	0	0
Metabolism and Nutrition Disorders						
Diabetes mellitus	3 (2.7%)	0	1 (1.0%)	0	0	0
Hypercholesterolemia	1 (0.9%)	3 (5.0%)	1 (1.0%)	0	0	2 (3.8%)
Hypokalemia	0	3 (5.0%)	0	0	0	0

Table 7: Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in any treatment arm), with a difference of $\geq 2\%$ between EYLEA and Sham in at least one study (COPERNICUS and GALILEO Studies, Week 24 to Week 76/100)

System organ class, Preferred term MedDRA Version 14.1	COPERNICUS		GALILEO			
	Week 24 to Week 100		Week 24 to Week 52		Week 52 to Week 76	
	EYLEA+PRN N=110	SHAM+PRN N=60	EYLEA+PRN N=97	SHAM N=57	EYLEA+PRN N= 91	SHAM+PRN N= 52
Musculoskeletal and Connective Tissue Disorders						
Arthralgia	4 (3.6%)	2 (3.3%)	2 (2.1%)	1 (1.8%)	2 (2.2%)	0
Back pain	4 (3.6%)	0	3 (3.1%)	0	1 (1.1%)	0
Bursitis	1 (0.9%)	2 (3.3%)	0	0	0	0
Osteoarthritis	3 (2.7%)	4 (6.7%)	1 (1.0%)	0	2 (2.2%)	0
Pain in extremity	1 (0.9%)	2 (3.3%)	1 (1.0%)	0	0	0
Nervous System Disorders						
Syncope	1 (0.9%)	2 (3.3%)	1 (1.0%)	2 (3.5%)	0	0
Psychiatric Disorders						
Anxiety	1 (0.9%)	2 (3.3%)	0	0	0	0
Renal and Urinary Disorders						
Renal failure acute	1 (0.9%)	2 (3.3%)	0	0	0	0
Respiratory, Thoracic and Mediastinal Disorders						
Hypoxia	0	2 (3.3%)	0	0	0	0
Vascular Disorders						
Hypertension	13 (11.8%)	9 (15.0%)	4 (4.1%)	4 (7.0%)	3 (3.3%)	2 (3.8%)

PRN: As needed (*pro re nata*)

Note: Patients are only counted once in each row but may appear in more than one row.

Treatment of BRVO

A total of 183 patients constituted the safety population in the EYLEA BRVO study (VIBRANT).

Patients in the EYLEA group (n=91) received EYLEA 2 mg, monthly up to week 24 and then received EYLEA every 2 months up to week 52. Patients in the laser control group received grid laser photocoagulation treatment at day 1 followed by sham injections monthly up to Week 24. Subjects in the laser arm became eligible for rescue treatment with EYLEA at week 24, and if pre-specified criteria were met, received 3 monthly 2 mg EYLEA injections, followed by 2 mg every two months. 67 patients in the laser control group received EYLEA rescue treatment after week 24.

The most common adverse drug reactions ($\geq 1\%$) which have been assessed as having reasonable or suspected relationship to either the study drug or the injection procedure in the BRVO study (VIBRANT) are presented in [Table 8](#).

Table 8: Adverse Drug Reactions ($\geq 1\%$) in BRVO Study (VIBRANT; Baseline to Week 24 and Week 24 to Week 52 weeks)

Preferred term MedDRA version 17.0	EYLEA (N=91)	Laser (N=92)	EYLEA (N=85)	Laser (N=83)	EYLEA Total ^b (N=152)
	Baseline to Week 24		Week 24 to Week 52 ^a		
Conjunctival hemorrhage	19.8%	4.3%	10.6%	13.3%	11.2%
Eye pain	4.4%	5.4%	1.2%	3.6%	2.0%
Foreign body sensation in eyes	3.3%	0%	1.2%	0%	0.7%
Lacrimation increased	3.3%	0%	1.2%	0%	0.7%
Cataract	2.2%	0%	1.2%	0%	0.7%
Corneal epithelium defect	2.2%	0%	0%	0%	0%
Intraocular pressure increased	2.2%	0%	2.4%	1.2%	2.0%
Ocular hyperemia	2.2%	2.2%	0%	1.2%	0%
Vitreous detachment	2.2%	0%	0%	2.4%	1.3%
Vitreous floaters	1.1%	0%	0%	0%	0%
Vision blurred	1.1%	1.1%	1.2%	2.4%	2.0%
Eyelid edema	1.1%	0%	1.2%	0%	0.7%
Cataract cortical	1.1%	0%	1.2%	0%	0.7%
Cataract subcapsular	1.1%	0%	0%	0%	0%
Cataract traumatic	1.1%	0%	0%	0%	0%
Injection site pain	1.1%	0%	0%	0%	0%
Corneal abrasion	0%	0%	2.4%	1.2%	2.0%
Punctate keratitis	0%	0%	1.2%	0%	0.7%
Hypersensitivity	0%	1.1%	1.2%	0%	0.7%

a As randomized in the BRVO (VIBRANT) study. Due to the study design, patients in the control (laser) arm may have received EYLEA injections and patients randomized to the EYLEA arm may have received laser treatment

b EYLEA Total = all patients who received at least one active EYLEA injection including patients who were previously in the laser control arm.

Note: Ocular ADR consider TEAE in study eye only. Patients are only counted once in each row but may appear in more than one row.

Treatment of DME

The data described in [Table 9](#) reflect exposure to EYLEA in two randomized, double-blind, laser controlled Phase III studies in (2Q4 n =291, 2Q8 n=287; laser: n=287) patients with up to 52 weeks of exposure to EYLEA.

Table 9: Adverse Drug Reactions with Incidence rate $\geq 1\%$ in either EYLEA treatment arms in at least one study (VIVID^{DME} and VISTA^{DME} Studies; 52 week data)^a

System/Organ Class Preferred Term (MedDRA Version 16.0)	Control (N=133)	VIVID^{DME} EYLEA 2Q4 (N=136)	EYLEA 2Q8 (N=135)	Control (N=154)	VISTA^{DME} EYLEA 2Q4 (N=155)	EYLEA 2Q8 (N=152)
Eye Disorders						
Cataract	3.8%	2.9%	5.9%	6.5%	7.1%	3.9%
Cataract cortical	0	2.2%	2.2%	1.9%	0.6%	2.6%
Cataract subcapsular	0	1.5%	0.7%	2.6%	1.3%	2.6%
Conjunctival hemorrhage	2.3%	22.8%	23.0%	30.5%	37.4%	27.6%
Conjunctival hyperemia	3.0%	2.2%	0.7%	0	1.9%	0.7%
Corneal erosion	1.5%	2.2%	3.7%	0	0	0
Eye pain	2.3%	6.6%	2.2%	9.7%	14.2%	11.8%
Foreign body sensation in eyes	1.5%	0.7%	3.0%	4.5%	5.2%	3.3%
Lacrimation increased	0	3.7%	2.2%	3.2%	4.5%	2.0%
Ocular hyperemia	0.8%	1.5%	4.4%	7.1%	3.9%	3.3%
Vision blurred	0.8%	0	1.5%	3.2%	5.2%	2.0%
Vitreous detachment	1.5%	1.5%	1.5%	5.2%	4.5%	5.9%
Vitreous floaters	0.8%	4.4%	1.5%	5.2%	9.7%	7.2%
General Disorders and Administration Site Conditions						
Injection site pain	0.8%	1.5%	1.5%	0	2.6%	1.3%
Injury, Poisoning and Procedural Complications						
Corneal abrasion	0	0	0	2.6%	1.9%	2.6%
Investigations						
Intraocular pressure increased	6.8%	8.8%	4.4%	0.6%	3.2%	3.9%

a As randomized in the VIVID^{DME} and VISTA^{DME} study. Due to the study design, patients in the control (laser) arm may have received EYLEA injections and patients randomized to the EYLEA arm may have received laser treatment

Note: Patients are only counted once in each row but may appear in more than one row.

Table 10: Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in any treatment arm), with a difference of $\geq 2\%$ between EYLEA and Control in at least one study (VIVID^{DME} and VISTA^{DME} Studies, 52 week data)^a

System/Organ Class Preferred Term (MedDRA Version 16.0)	VIVID ^{DME}			VISTA ^{DME}		
	Control N=133	EYLEA 2Q4 N=136	EYLEA 2Q8 N=135	Control N=154	EYLEA 2Q4 N=155	EYLEA 2Q8 N=152
Blood and Lymphatic System Disorders						
Anemia	1 (0.8%)	2 (1.5%)	3 (2.2%)	6 (3.9%)	13 (8.4%)	10 (6.6%)
Cardiac Disorders						
Arrhythmia	0	3 (2.2%)	0	1 (0.6%)	0	0
Atrial fibrillation	1 (0.8%)	1 (0.7%)	1 (0.7%)	4 (2.6%)	1 (0.6%)	2 (1.3%)
Cardiac failure	0	3 (2.2%)	1 (0.7%)	0	0	0
Cardiac failure congestive	0	0	1 (0.7%)	1 (0.6%)	8 (5.2%)	6 (3.9%)
Myocardial infarction	0	1 (0.7%)	0	1 (0.6%)	4 (2.6%)	2 (1.3%)
Eye Disorders						
Blepharitis	1 (0.8%)	1 (0.7%)	3 (2.2%)	3 (1.9%)	0	6 (3.9%)
Cataract	5 (3.8%)	4 (2.9%)	8 (5.9%)	10 (6.5%)	11 (7.1%)	6 (3.9%)
Cataract cortical	0	3 (2.2%)	3 (2.2%)	3 (1.9%)	1 (0.6%)	4 (2.6%)
Cataract nuclear	2 (1.5%)	0	2 (1.5%)	4 (2.6%)	2 (1.3%)	0
Conjunctival hemorrhage	3 (2.3%)	31 (22.8%)	31 (23.0%)	47 (30.5%)	58 (37.4%)	42 (27.6%)
Conjunctival hyperemia	4 (3.0%)	3 (2.2%)	1 (0.7%)	0	3 (1.9%)	1 (0.7%)
Corneal erosion	2 (1.5%)	3 (2.2%)	5 (3.7%)	0	0	0
Cystoid macular edema	7 (5.3%)	1 (0.7%)	5 (3.7%)	3 (1.9%)	0	1 (0.7%)
Diabetic retinal edema	5 (3.8%)	2 (1.5%)	2 (1.5%)	3 (1.9%)	0	0
Diabetic retinopathy	2 (1.5%)	0	0	6 (3.9%)	0	2 (1.3%)
Dry eye	4 (3.0%)	3 (2.2%)	2 (1.5%)	7 (4.5%)	12 (7.7%)	2 (1.3%)
Eye pain	3 (2.3%)	9 (6.6%)	3 (2.2%)	15 (9.7%)	22 (14.2%)	18 (11.8%)
Lacrimation increased	0	5 (3.7%)	3 (2.2%)	5 (3.2%)	7 (4.5%)	3 (2.0%)
Macular cyst	3 (2.3%)	0	0	0	0	1 (0.7%)
Macular edema	4 (3.0%)	0	2 (1.5%)	2 (1.3%)	0	0
Maculopathy	3 (2.3%)	1 (0.7%)	0	0	0	0
Ocular hyperemia	1 (0.8%)	2 (1.5%)	6 (4.4%)	11 (7.1%)	6 (3.9%)	5 (3.3%)
Ocular hypertension	0	8 (5.9%)	3 (2.2%)	0	2 (1.3%)	0
Photopsia	0	0	0	5 (3.2%)	2 (1.3%)	1 (0.7%)
Punctate keratitis	2 (1.5%)	5 (3.7%)	6 (4.4%)	1 (0.6%)	4 (2.6%)	2 (1.3%)
Retinal aneurysm	3 (2.3%)	4 (2.9%)	6 (4.4%)	2 (1.3%)	1 (0.6%)	3 (2.0%)
Retinal exudates	9 (6.8%)	5 (3.7%)	10 (7.4%)	7 (4.5%)	6 (3.9%)	3 (2.0%)

Table 10: Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in any treatment arm), with a difference of $\geq 2\%$ between EYLEA and Control in at least one study (VIVID^{DME} and VISTA^{DME} Studies, 52 week data)^a

System/Organ Class Preferred Term (MedDRA Version 16.0)	VIVID ^{DME}			VISTA ^{DME}		
	Control N=133	EYLEA 2Q4 N=136	EYLEA 2Q8 N=135	Control N=154	EYLEA 2Q4 N=155	EYLEA 2Q8 N=152
Retinal hemorrhage	10 (7.5%)	5 (3.7%)	8 (5.9%)	11 (7.1%)	4 (2.6%)	4 (2.6%)
Retinal neovascularisation	6 (4.5%)	1 (0.7%)	0	7 (4.5%)	2 (1.3%)	2 (1.3%)
Retinal vascular disorder	1 (0.8%)	3 (2.2%)	3 (2.2%)	0	1 (0.6%)	3 (2.0%)
Retinopathy	3 (2.3%)	0	0	0	0	0
Vision blurred	1 (0.8%)	0	2 (1.5%)	5 (3.2%)	8 (5.2%)	3 (2.0%)
Visual acuity reduced	17 (12.8%)	5 (3.7%)	10 (7.4%)	8 (5.2%)	2 (1.3%)	5 (3.3%)
Visual impairment	2 (1.5%)	0	2 (1.5%)	5 (3.2%)	0	3 (2.0%)
Vitreous floaters	1 (0.8%)	6 (4.4%)	2 (1.5%)	8 (5.2%)	15 (9.7%)	11 (7.2%)
Vitreous hemorrhage	3 (2.3%)	3 (2.2%)	3 (2.2%)	8 (5.2%)	7 (4.5%)	1 (0.7%)
Gastrointestinal Disorders						
Abdominal pain	0	0	0	6 (3.9%)	3 (1.9%)	2 (1.3%)
Constipation	1 (0.8%)	1 (0.7%)	3 (2.2%)	8 (5.2%)	8 (5.2%)	3 (2.0%)
Dental caries	2 (1.5%)	1 (0.7%)	1 (0.7%)	0	0	3 (2.0%)
Diarrhea	0	2 (1.5%)	3 (2.2%)	9 (5.8%)	11 (7.1%)	4 (2.6%)
Gastritis	0	3 (2.2%)	1 (0.7%)	2 (1.3%)	1 (0.6%)	1 (0.7%)
General Disorders and Administration Site Conditions						
Chest pain	0	0	0	8 (5.2%)	3 (1.9%)	5 (3.3%)
Edema peripheral	2 (1.5%)	1 (0.7%)	1 (0.7%)	6 (3.9%)	14 (9.0%)	10 (6.6%)
Fatigue	0	0	1 (0.7%)	1 (0.6%)	4 (2.6%)	1 (0.7%)
Injection site pain	1 (0.8%)	2 (1.5%)	2 (1.5%)	0	4 (2.6%)	2 (1.3%)
Pyrexia	1 (0.8%)	0	0	0	4 (2.6%)	4 (2.6%)
Immune System Disorders						
Hypersensitivity	0	0	0	0	4 (2.6%)	0
Infections and Infestations						
Bronchitis	4 (3.0%)	7 (5.1%)	1 (0.7%)	8 (5.2%)	7 (4.5%)	4 (2.6%)
Cellulitis	0	0	0	5 (3.2%)	9 (5.8%)	9 (5.9%)
Cystitis	0	1 (0.7%)	0	1 (0.6%)	4 (2.6%)	1 (0.7%)
Ear infection	0	0	1 (0.7%)	0	1 (0.6%)	3 (2.0%)
Gastroenteritis	1 (0.8%)	0	1 (0.7%)	5 (3.2%)	2 (1.3%)	1 (0.7%)
Nasopharyngitis	20 (15.0%)	25 (18.4%)	22 (16.3%)	13 (8.4%)	12 (7.7%)	9 (5.9%)

Table 10: Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in any treatment arm), with a difference of $\geq 2\%$ between EYLEA and Control in at least one study (VIVID^{DME} and VISTA^{DME} Studies, 52 week data)^a

System/Organ Class Preferred Term (MedDRA Version 16.0)	VIVID ^{DME}			VISTA ^{DME}		
	Control N=133	EYLEA 2Q4 N=136	EYLEA 2Q8 N=135	Control N=154	EYLEA 2Q4 N=155	EYLEA 2Q8 N=152
Pharyngitis	0	0	3 (2.2%)	0	1 (0.6%)	1 (0.7%)
Pneumonia	1 (0.8%)	2 (1.5%)	1 (0.7%)	3 (1.9%)	8 (5.2%)	4 (2.6%)
Tooth infection	0	0	0	0	0	3 (2.0%)
Urinary tract infection	2 (1.5%)	2 (1.5%)	4 (3.0%)	11 (7.1%)	11 (7.1%)	14 (9.2%)
Investigations						
Blood creatine phosphokinase increased	2 (1.5%)	0	0	7 (4.5%)	3 (1.9%)	2 (1.3%)
Blood glucose increased	2 (1.5%)	6 (4.4%)	4 (3.0%)	3 (1.9%)	4 (2.6%)	2 (1.3%)
Blood potassium increased	1 (0.8%)	0	1 (0.7%)	5 (3.2%)	2 (1.3%)	1 (0.7%)
Glycosylated hemoglobin increased	4 (3.0%)	8 (5.9%)	4 (3.0%)	4 (2.6%)	2 (1.3%)	5 (3.3%)
Intraocular pressure increased	9 (6.8%)	12 (8.8%)	6 (4.4%)	1 (0.6%)	5 (3.2%)	6 (3.9%)
Visual acuity tests abnormal	19 (14.3%)	4 (2.9%)	8 (5.9%)	4 (2.6%)	2 (1.3%)	1 (0.7%)
Metabolism and Nutrition Disorders						
Diabetes mellitus	3 (2.3%)	2 (1.5%)	6 (4.4%)	11 (7.1%)	6 (3.9%)	10 (6.6%)
Hypercholesterolemia	3 (2.3%)	2 (1.5%)	2 (1.5%)	6 (3.9%)	2 (1.3%)	1 (0.7%)
Hyperglycemia	4 (3.0%)	1 (0.7%)	1 (0.7%)	7 (4.5%)	1 (0.6%)	2 (1.3%)
Hypoglycemia	2 (1.5%)	0	3 (2.2%)	2 (1.3%)	8 (5.2%)	2 (1.3%)
Hyponatremia	0	0	1 (0.7%)	1 (0.6%)	0	4 (2.6%)
Vitamin D deficiency	0	0	0	6 (3.9%)	2 (1.3%)	3 (2.0%)
Musculoskeletal and Connective Tissue Disorders						
Muscle spasms	0	0	0	6 (3.9%)	3 (1.9%)	2 (1.3%)
Musculoskeletal pain	1 (0.8%)	1 (0.7%)	3 (2.2%)	4 (2.6%)	1 (0.6%)	2 (1.3%)
Osteoarthritis	0	1 (0.7%)	2 (1.5%)	6 (3.9%)	1 (0.6%)	3 (2.0%)
Neoplasms Benign, Malignant and Unspecified (incl Cysts and Polyps)						
Basal cell carcinoma	1 (0.8%)	0	0	0	1 (0.6%)	3 (2.0%)
Nervous System Disorders						
Headache	2 (1.5%)	3 (2.2%)	2 (1.5%)	13 (8.4%)	13 (8.4%)	6 (3.9%)
Syncope	0	1 (0.7%)	0	5 (3.2%)	2 (1.3%)	1 (0.7%)

Table 10: Ocular and non-ocular adverse events, regardless of relationship to treatment (treatment emergent adverse events with incidence rate $\geq 1\%$ in any treatment arm), with a difference of $\geq 2\%$ between EYLEA and Control in at least one study (VIVID^{DME} and VISTA^{DME} Studies, 52 week data)^a

System/Organ Class Preferred Term (MedDRA Version 16.0)	VIVID ^{DME}			VISTA ^{DME}		
	Control N=133	EYLEA 2Q4 N=136	EYLEA 2Q8 N=135	Control N=154	EYLEA 2Q4 N=155	EYLEA 2Q8 N=152
Psychiatric Disorders						
Anxiety	1 (0.8%)	2 (1.5%)	1 (0.7%)	6 (3.9%)	4 (2.6%)	2 (1.3%)
Renal and Urinary Disorders						
Hematuria	0	0	0	4 (2.6%)	1 (0.6%)	2 (1.3%)
Renal failure	1 (0.8%)	0	1 (0.7%)	3 (1.9%)	6 (3.9%)	3 (2.0%)
Renal failure chronic	0	1 (0.7%)	0	1 (0.6%)	6 (3.9%)	4 (2.6%)
Urine abnormality	0	0	0	4 (2.6%)	0	3 (2.0%)
Respiratory, Thoracic and Mediastinal Disorders						
Cough	4 (3.0%)	2 (1.5%)	5 (3.7%)	6 (3.9%)	13 (8.4%)	5 (3.3%)
Dyspnea	0	0	1 (0.7%)	5 (3.2%)	8 (5.2%)	7 (4.6%)
Oropharyngeal pain	5 (3.8%)	1 (0.7%)	1 (0.7%)	1 (0.6%)	1 (0.6%)	0
Skin and Subcutaneous Tissue Disorders						
Skin ulcer	3 (2.3%)	0	0	3 (1.9%)	1 (0.6%)	3 (2.0%)
Vascular Disorders						
Hypertension	17 (12.8%)	16 (11.8%)	19 (14.1%)	34 (22.1%)	38 (24.5%)	28 (18.4%)

a As randomized in the VIVID^{DME} and VISTA^{DME} study. Due to the study design, patients in the control (laser) arm may have received EYLEA injections and patients randomized to the EYLEA arm may have received laser treatment

Note: Patients are only counted once in each row but may appear in more than one row.

Treatment of myopic CNV

A total of 122 patients from Japan, South Korea, Singapore, Taiwan and Hong Kong constituted the safety population in the EYLEA myopic CNV study (MYRROR).

Patients in the EYLEA group (n=91) received EYLEA 2 mg administered once at study start and then as needed (PRN) up to week 44.

Patients in the sham arm (n=31) received sham injections every 4 weeks through Week 20. Patients in the sham arm received a mandatory first dose of EYLEA at week 24, followed by additional EYLEA injections, if pre-specified criteria were met, up to Week 44.

The most common adverse drug reactions ($\geq 1\%$) in the MYRROR study are presented in [Table 11](#).

Table 11: Adverse Drug Reactions with Incidence Rate $\geq 1\%$ in Patients Treated with EYLEA or Sham (MYRROR, baseline up to 48 weeks)

System/Organ Class Preferred Term	EYLEA ^a	Sham ^b	EYLEA ^a	Sham+EYLEA ^c
	(n=91) %	(n=31) %	(n=91) %	(n=31) %
	Baseline to Week 24		Baseline to Week 48	
Eye disorders				
Cataract subcapsular	0	0	1 (1.1%)	0
Conjunctival haemorrhage	6 (6.6%)	1 (3.2%)	10 (11.0%)	1 (3.2%)
Corneal erosion	2 (2.2%)	1 (3.2%)	2 (2.2%)	1 (3.2%)
Eye pain	6 (6.6%)	1 (3.2%)	7 (7.7%)	1 (3.2%)
Ocular hyperaemia	2 (2.2%)	1 (3.2%)	2 (2.2%)	1 (3.2%)
Punctate keratitis	4 (4.4%)	3 (9.7%)	6 (6.6%)	3 (9.7%)
Retinal detachment excluding LLT subretinal fluid	0	1 (3.2%)	0	1 (3.2%)
Retinal detachment including LLT subretinal fluid	0	1 (3.2%)	0	1 (3.2%)
Retinal tear	1 (1.1%)	0	1 (1.1%)	0
Vitreous floaters	0	0	1 (1.1%)	0

a EYLEA administered at baseline and additional injection in case of disease persistence or reoccurrence

b Received sham injections every 4 weeks through Week 20

c Mandatory injection of EYLEA at Week 24, thereafter additional injection in case of disease persistence or reoccurrence

Note: Patients are only counted once in each row but may appear in more than one row.

Less Common Clinical Trial Adverse Drug Reactions

Treatment of wet AMD

Less common adverse drug reactions reported in $<1\%$ of the patients treated with EYLEA for up to 96 weeks in the Phase III studies VIEW1 and VIEW2.

Eye Disorders: abnormal sensation in eye, anterior chamber flare, cataract cortical, corneal epithelium defect, corneal erosion, eyelid irritation, iridocyclitis, iritis, lenticular opacities, retinal tear, uveitis, vitritis.

General disorders and administration site conditions: injection site irritation

Immune System Disorders: hypersensitivity

Infections and Infestations: endophthalmitis, hypopyon

Treatment of CRVO

Less common adverse reactions reported in <1% of the patients treated with EYLEA for up to 76/100 weeks in the Phase III studies COPERNICUS and GALILEO.

Eye Disorders: cataract subcapsular, conjunctival hyperemia, corneal epithelium defect, corneal edema, detachment of retinal pigment epithelium, eyelid edema, iridocyclitis, and iritis.

Infections and Infestations: endophthalmitis¹

Treatment of BRVO

There were no less common adverse reactions reported in <1% of the patients treated with EYLEA for up to 52 weeks in the BRVO Phase III study (VIBRANT).

Treatment of DME

Less common adverse reactions reported in <1% of the patients treated with EYLEA for up to 52 weeks in the Phase III studies VIVID^{DME} and VISTA^{DME}.

Eye Disorders: abnormal sensation in eye, anterior chamber flare, cataract nuclear, corneal epithelium defect, corneal edema, eyelid edema, eyelid irritation, iridocyclitis, iritis, lenticular opacities, retinal detachment, retinal tear, uveitis

General disorders and administration site conditions: injection site hemorrhage, injection site irritation

Drug related hypersensitivity, hypopyon, vitritis, endophthalmitis, retinal pigment epithelium tear, and detachment of the retinal pigment epithelium were not reported in the study eye.

Treatment of myopic CNV

There were no less common adverse reactions reported in <1% of patients treated with EYLEA for up to 48 weeks in the myopic CNV Phase III study (MYRROR).

Abnormal Hematologic and Clinical Chemistry Findings

There were no hematologic or clinical chemistry ADRs seen in Phase III wet AMD and DME studies.

There were no trends indicating an association with EYLEA and the development of clinically significant abnormal hematologic and clinical chemistry in the Phase III CRVO, BRVO, and myopic CNV studies.

¹ Culture positive and culture negative endophthalmitis

Post-Market Adverse Drug Reactions

Intraocular inflammation has been reported in association with the use of EYLEA during the post-marketing experience i.e., endophthalmitis (infectious and non-infectious), anterior chamber flare, iridocyclitis, uveitis, iritis, vitritis and hypopyon. These were consistent with the findings from the clinical trials.

During the post-marketing period, reports of hypersensitivity included rash, pruritus, urticaria, and isolated cases of severe anaphylactic/anaphylactoid reactions.

DRUG INTERACTIONS

Overview

No formal drug interaction studies have been performed with EYLEA. EYLEA must not be mixed with other medicinal products.

Adjunctive use of verteporfin photodynamic therapy (PDT) and EYLEA has not been studied.

The safety and efficacy of wet AMD patients who were previously treated with laser photocoagulation have not been studied.

DOSAGE AND ADMINISTRATION

FOR OPHTHALMIC INTRAVITREAL INJECTION ONLY.

The EYLEA vial is for single-use only. The vial contents should not be split or further compounded. Use of more than one injection from a vial may increase the risk of contamination and subsequent infection. EYLEA vials do not contain any preservative agent (see **DOSAGE FORMS, COMPOSITION AND PACKAGING**).

Dosing Considerations

- EYLEA must only be administered by a qualified physician experienced in administering intravitreal injections.

Recommended Dose and Dosage Adjustment

Treatment of wet AMD

The recommended dose for EYLEA is 2 mg (0.05 mL or 50 microliters) administered by intravitreal injection every month (4 weeks) for the first 3 months, followed by 2 mg (0.05 mL) via intravitreal injection every 2 months (8 weeks).

After the first 12 months of treatment with EYLEA, the treatment interval could be extended up to every 3 months (12 weeks) based on visual and/or anatomic outcomes. Patients should be evaluated regularly.

In AMD clinical trials, additional efficacy was not demonstrated when EYLEA was dosed every 4 weeks compared to every 8 weeks (see **PART II: SCIENTIFIC INFORMATION – CLINICAL TRIALS – Treatment of Wet AMD: Study Demographics and Trial Design**).

Treatment of CRVO and BRVO

The recommended dose for EYLEA is 2 mg (0.05 mL or 50 microliters) administered by intravitreal injection once every month (4 weeks). The interval between two doses should not be shorter than one month. The treatment interval may be extended up to 3 months (12 weeks) based on visual and anatomic outcomes. Prescribers are advised to periodically assess (every 1 to 2 months) the need for continued therapy.

Clinical trial experience of a monthly dosing regimen of 2 mg aflibercept beyond 6 months in the CRVO and BRVO indications is limited. The dosing regimen of once every 4 weeks changed at 24 weeks to a regimen that allowed for extension of the treatment interval based on visual and anatomic outcomes in the CRVO clinical trials and to once every 8 weeks in the BRVO clinical trial (see [PART II: SCIENTIFIC INFORMATION – CLINICAL TRIALS](#)).

Treatment of DME

The recommended dose for EYLEA is 2 mg aflibercept (equivalent to 50 microliters solution for injection) administered by intravitreal injection monthly (once every 4 weeks) for the first 5 consecutive doses, followed by one injection every 2 months (8 weeks).

EYLEA dosed as frequently as 2 mg every month showed similar efficacy to EYLEA dosed 2 mg once every 2 months in the DME clinical trials.

Treatment of myopic CNV

The recommended dose for EYLEA is a single intravitreal injection of 2 mg aflibercept (equivalent to 50 microliters solution for injection).

Additional doses should be administered only if visual and/or anatomic outcomes indicate that the disease persists. The interval between two doses should not be shorter than one month (4 weeks). Recurrences are treated like a new manifestation of the disease.

Special Populations

No specific studies in patients with hepatic and/or renal impairment were conducted with EYLEA.

Geriatrics: No special dosing considerations are needed in elderly populations.

Pediatrics (< 18 years of age): Wet AMD does not occur in children and adolescents. The safety and efficacy of EYLEA have not been studied in pediatric patients in the indications wet AMD, CRVO, BRVO, DME, and myopic CNV.

Administration

Intravitreal injections must be carried out by a qualified physician experienced in administering intravitreal injections, and according to medical standards and under controlled aseptic conditions, which include surgical hand disinfection and the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). The peri-ocular skin, eyelid and ocular surface should be disinfected. Adequate anesthesia and a topical broad spectrum microbicide should be used prior to the injection.

Prior to administration visually inspect the solution for injection. Do not use the vial if particulates, cloudiness, or discoloration are visible.

For the intravitreal injection a 30 G x ½ inch injection needle (not supplied) should be used.

Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, sterile equipment for paracentesis should be available.

Following intravitreal injection patients should be instructed to report any symptoms suggestive of endophthalmitis, retinal detachment or tear, cataract or increased intraocular pressure (eg, eye pain, redness of the eye, photophobia, blurring or loss of vision) without delay.

THE VIAL IS FOR SINGLE-USE ONLY. EACH VIAL IS TO BE USED ONLY FOR THE TREATMENT OF ONE EYE WITH 50 microliters (2 mg) OF EYLEA.

AFTER INJECTION, ANY UNUSED PRODUCT MUST BE DISCARDED.

Prior to usage, the unopened vial of EYLEA may be stored at room temperature (25°C) for up to 24 hours. After opening the vial, proceed under aseptic conditions.

To prepare EYLEA for intravitreal injection, please adhere to the following instructions:

Vials:

1. Remove the protective plastic cap from the vial (see [Figure 1](#)).



Figure 1

2. Clean the top of the vial with an alcohol wipe (see [Figure 2](#))



Figure 2

3. Remove the 18 G, 5-micron filter needle supplied in the carton from its pouch. Attach the filter needle to a 1-mL sterile, Luer-lock syringe (not supplied) by twisting it onto the Luer lock syringe tip (see [Figure 3](#)).




Figure 3

4. Push the filter needle into the centre of the vial stopper until the needle is completely inserted into the vial and the tip touches the bottom edge of the vial.
5. Using aseptic technique withdraw all of the EYLEA vial contents into the syringe, keeping the vial in an upright position, slightly inclined to ease complete withdrawal. To deter the introduction of air, ensure the bevel of the filter needle is submerged into the liquid. Continue to tilt the vial during withdrawal keeping the bevel of the filter needle submerged in the liquid (see [Figure 4](#) and [Figure 5](#)).




Figure 4




Figure 5

6. Ensure that the plunger rod is drawn sufficiently back when emptying the vial in order to completely empty the filter needle. After injection, any unused product must be discarded.
7. Remove the filter needle from the syringe and properly dispose of the filter needle.

Note: Filter needle is **not** to be used for intravitreal injection.

8. Using aseptic technique, attach a 30 G x ½ inch injection needle (not supplied) to the syringe by firmly twisting the injection needle onto the Luer-lock syringe tip (see [Figure 6](#)).




Figure 6

9. Holding the syringe with the needle pointing up, check the syringe for bubbles. If there are bubbles, **gently tap** the syringe with your finger until the bubbles rise to the top (see [Figure 7](#)).




Figure 7

10. To eliminate all of the bubbles and to expel excess drug, **slowly** depress the plunger so that the plunger tip aligns with the line that marks 0.05 mL on the syringe (see [Figure 8](#) and [Figure 9](#)).




Figure 8




Figure 9

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Cases of accidental overdose have been reported from the clinical studies. Adverse reactions most frequently associated with these reported cases were intraocular pressure increased and eye pain.

Overdosing with increased injection volume may increase intraocular pressure. Therefore, in case of an overdose, intraocular pressure should be monitored and if deemed necessary by the treating physician, adequate treatment should be initiated.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of pro-angiogenic factors that can act as potent mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via 2 receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leukocytes. Excessive activation of these receptors by VEGF-A can result in pathological neovascularization and excessive vascular permeability which is believed to contribute to vision loss in a variety of ocular diseases.

Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF with higher affinity than their natural receptors, and thereby can inhibit the binding and activation of these cognate VEGF receptors. (1)

Pharmacodynamics

Treatment of wet AMD

Data on pharmacodynamics effect of aflibercept, measured by central retinal thickness (CRT) and change in choroidal neovascularization (CNV) area, showed variable results across Phase I and Phase II studies. In the Phase III studies (VIEW1 and VIEW2), similar results on decrease in mean CNV area and CRT from baseline to Week 52 were reported for all 3 aflibercept treatment groups (0.5Q4, 2Q4, 2Q8). At Week 52 in VIEW 1, the mean change from baseline in CRT (EYLEA 2Q8 vs. ranibizumab 0.5Q4) was -130 microns vs. -129 microns, and at Week 96, was -121 microns vs. -114 microns. At Week 52 in VIEW 2, the mean change from baseline in CRT (EYLEA 2Q8 vs. ranibizumab 0.5Q4) was -149 microns vs. -139 microns, and at Week 96/100, was -145 microns vs. -121 microns.

Treatment of CRVO

Reductions in mean retinal thickness (microns, EYLEA vs. Sham) were observed in GALILEO (-449 vs. -169) and COPERNICUS (-457 vs. -145) at week 24 compared to baseline. However, the clinical relevance of these data is yet to be determined.

Treatment of BRVO

At week 24 the mean changes in retinal thickness in the EYLEA vs. the laser group were -280 microns vs. -128 microns.

Treatment of DME

A reduction in CRT was observed in patients treated with EYLEA in the VIVID^{DME} and VISTA^{DME} DME clinical trials. At 52 weeks, the mean change from baseline in CRT (microns, EYLEA 2Q8 vs. Control) was -192.4 vs. -66.2 (VIVID^{DME}) and -183.1 vs. -73.3 (VISTA^{DME}).

Treatment of myopic CNV

In patients treated with EYLEA (one injection given at start of therapy, additional injection given in case of disease persistence or recurrence) retinal thickness was assessed by OCT. The mean change in CRT (microns, EYLEA vs. Sham) from baseline to week 24 was -79 vs. -4. The mean change in CRT through Week 48 was -83 vs. -57.

Pharmacokinetics

EYLEA is administered directly into the vitreous to exert local effects in the eye.

Absorption

Following intravitreal administration of aflibercept, a fraction of the administered dose is expected to bind with free endogenous VEGF to form an inactive VEGF: aflibercept complex in the eye. From the ocular space, free and bound aflibercept are slowly absorbed into the systemic circulation where it is predominately observed as the inactive stable complex with VEGF; however, only "free aflibercept" is able to bind endogenous VEGF. Peak plasma concentrations (C_{max}) of free aflibercept are reached within 1 to 3 days after administration.

Distribution

In a pharmacokinetic substudy with frequent sampling in wAMD patients, maximum plasma concentrations of free aflibercept (systemic C_{max}) were low, with a mean of approximately 0.02 microgram/mL (range 0 to 0.054 microgram/mL) within 1 to 3 days after a 2 mg intravitreal injection, and were undetectable 2 weeks following dosage in almost all patients. Aflibercept does not accumulate in the plasma when administered intravitreally every 4 weeks.

It is estimated that after intravitreal administration of 2 mg to patients, the mean maximum plasma concentration of free aflibercept is more than a 100 fold lower than the concentration of aflibercept required to half-maximally bind systemic VEGF (2.91 microgram/mL) in a study of healthy volunteers. (2)

These pharmacokinetic results were consistent in pharmacokinetic sub-studies in patients with CRVO, BRVO, DME, and myopic CNV with mean C_{max} of free aflibercept in plasma in the range of 0.03 to 0.05 microgram/mL. Plasma concentrations of free aflibercept declined to values below or close to the lower limit of quantitation generally within one week; undetectable concentrations were reached after two weeks in all patients.

Metabolism

As EYLEA is a protein-based therapeutic, no metabolism studies have been conducted.

Excretion

Aflibercept is expected to be eliminated through both binding to endogenous VEGF and a slower non-saturable clearance (e.g., proteolysis) mechanism. (3)

Special Populations and Conditions

Geriatrics

No special considerations are needed.

Pediatrics (< 18 years of age)

Wet AMD does not occur in children or adolescents. The safety and efficacy of EYLEA have not been studied in pediatric patients in the indications wet AMD, CRVO, BRVO, DME, and myopic CNV.

Renal Insufficiency

No special studies in patients with renal impairment were conducted with EYLEA.

Pharmacokinetic analysis of wet AMD patients in the VIEW2 study, of which 40% had renal impairment (24% mild, 15% moderate, and 1% severe), revealed no differences with respect to plasma concentrations of active drug after intravitreal administration every 4 or 8 weeks.

Similar results were seen in patients with CRVO in the GALILEO study.

Pharmacokinetic analysis of DME patients in the VIVID^{DME} study, of which 47% had renal impairment (35% mild, 10% moderate, and 2% severe), detected no difference in free aflibercept concentrations in patients with different renal function.

Similar results were seen in patients with myopic CNV in the MYRROR study.

STORAGE AND STABILITY

Store in a refrigerator (2°C to 8°C). Do not freeze.

Keep the vial in the outer carton in order to protect from light.

SPECIAL HANDLING INSTRUCTIONS

THE VIAL IS FOR SINGLE USE IN ONE EYE ONLY. Prior to administration visually inspect the solution for injection. Do not use the vial if particulates, cloudiness, or discoloration are visible.

Prior to usage, the unopened vial of EYLEA may be stored at room temperature (25°C) for up to 24 hours. After opening the vial, proceed under aseptic conditions.

For the intravitreal injection, a 30 G x ½ inch injection needle should be used.

DOSAGE FORMS, COMPOSITION AND PACKAGING

EYLEA is provided as a sterile, clear, colourless to pale yellow, iso-osmotic, preservative-free aqueous solution containing polysorbate 20; sodium phosphate, monobasic, monohydrate; sodium phosphate, dibasic, heptahydrate; sodium chloride; sucrose and water for injection.

One millilitre solution for intravitreal injection contains 40 mg aflibercept.

Vials

Each carton includes a type I glass vial containing a fill volume of 278 microliter solution for intravitreal injection with an elastomeric rubber stopper, and an 18 G filter needle.

Each vial contains a fill volume of 278 microliter solution for intravitreal injection which provides approximately 100 microliter of extractable volume. Each vial provides a usable amount to deliver a single dose of 50 microliters containing 2 mg aflibercept.

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, ie, essentially 'sodium-free'.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name:	Aflibercept
Chemical name:	des-432-lysine-[human vascular endothelial growth factor receptor 1-(103-204)-peptide (containing Ig-like C2-type 2 domain) fusion protein with human vascular endothelial growth factor receptor 2-(206-308)-peptide (containing Ig-like C2-type 3 domain fragment) fusion protein with human immunoglobulin G1-(227 C-terminal residues)-peptide (Fc fragment)], (211-211':214-214')-bisdisulfide dimer
Molecular formula:	$C_{4318}H_{6788}N_{1164}O_{1304}S_{32}$
Molecular weight:	Without glycolysation: 97 kDa With glycolysation: 115 kDa
Structural formula:	<p>VEGFR1 VEGFR2 Aflibercept</p> <p>The diagram shows the structural formula of Aflibercept. It consists of two VEGFR1 chains (left, blue circles 1-7) and two VEGFR2 chains (middle, yellow circles 1-7) connected to a common backbone. To the right, the Aflibercept dimer is shown, consisting of two VEGFR1 chains (blue circles 2, 3) and two VEGFR2 chains (yellow circles 2, 3) connected to a common backbone, with an IgG1 Fc fragment attached to the bottom of the dimer.</p>
Physicochemical properties:	Aflibercept is a dimeric glycoprotein. The solution for intravitreal administration is a sterile, clear, and colourless to pale yellow, iso-osmotic solution.
pH:	6.2

CLINICAL TRIALS

Treatment of Wet AMD

Study Demographics and Trial Design

The safety and efficacy of EYLEA (aflibercept, solution for intravitreal injection) were assessed in 2 randomized, multi-center, double-blind, active-controlled studies in patients with wet AMD. VIEW1 was conducted in Canada and the United States of America. VIEW2 was conducted in Europe, Latin America and Asia. A total of 2412 patients were treated and evaluable for efficacy (1817 with EYLEA) in the 2 Phase III studies (VIEW1 and VIEW2). (4) In each study, patients were randomly assigned in a 1:1:1:1 ratio to 1 of 4 dosing regimens. Administration in 2 of the EYLEA arms was every 4 weeks, and in the third arm, administration was extended to a longer dosing interval of every 8 weeks:

- 1) EYLEA administered at 2 mg every 8 weeks following 3 initial monthly doses (EYLEA 2Q8),
- 2) EYLEA administered at 2 mg every 4 weeks (EYLEA 2Q4),
- 3) EYLEA administered at 0.5 mg every 4 weeks (EYLEA 0.5Q4), and
- 4) Ranibizumab administered at 0.5 mg every 4 weeks (ranibizumab 0.5Q4)

In the second year of the studies, patients continued to receive the dosage strength to which they were initially randomized but on a modified dosing schedule guided by pre-specified retreatment criteria with a protocol-defined maximum dosing interval of 12 weeks:

- Increase in central retinal thickness (CRT) of ≥ 100 μm compared to the lowest previous value as measured by optical coherence tomography (OCT), or
- A loss from the best previous letter score of ≥ 5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in conjunction with recurrent fluid as indicated by OCT, or
- New or persistent fluid as indicated by OCT, or
- New onset classic neovascularization, or
- New or persistent leak on fluorescein angiography (FA), or
- New macular hemorrhage, or
- 12 weeks have elapsed since the previous injection.

The primary efficacy endpoint was the proportion of patients who maintained vision (i.e., loss of fewer than 15 letters of BCVA compared to Baseline) at Week 52. The non-inferiority margin was 10%. The secondary efficacy variables included changes from Baseline to Week 52 in (1) BCVA (ETDRS letter score); (2) the proportion of patients who gained 15 or more letters; (3) total NEI VFQ-25 (National Eye Institute 25-item Visual Function Questionnaire) score; and (4) CNV (choroidal neovascularisation) area as assessed by fluorescein angiography (FA).

Patients ranged in age from 49 to 99 years (with a mean of 76 years) with primarily active subfoveal CNV lesions secondary to wet AMD, also including juxtafoveal lesions, as seen on FA. In the clinical studies, approximately 89% (1616/1817) of the patients randomized to treatment with EYLEA were 65 years of age or older and approximately 63% (1139/1817) were 75 years of age or older.

Table 12 – Summary of Patient Demographics for Clinical Trials in wet AMD

Study No.	Trial Design	Dosage, route of administration, and duration	Study Subjects (n= number)	Mean Age (Range)	Gender
VIEW1	randomized, multi-center, double-blind, active-controlled	Intravitreal injection	EYLEA 2Q8: n= 303	78.1 (49-99 years)	Male: 41.2% Female: 58.8%
		<ul style="list-style-type: none"> EYLEA administered at 2 mg every 8 weeks following 3 initial monthly doses (EYLEA 2Q8), 	EYLEA 2Q4: n= 304		
		<ul style="list-style-type: none"> EYLEA administered at 2 mg every 4 weeks (EYLEA 2Q4), 	EYLEA 0.5Q4: n=304		
		<ul style="list-style-type: none"> EYLEA administered at 0.5 mg every 4 weeks (EYLEA 0.5Q4), and 	ranibizumab 0.5mgQ4: n=306		
VIEW2		<ul style="list-style-type: none"> EYLEA administered at 0.5 mg every 4 weeks (EYLEA 0.5Q4), and Ranibizumab administered at 0.5 mg every 4 weeks (ranibizumab 0.5Q4) 	EYLEA 2Q8: n= 313	73.9 (50-93 years)	Male: 44.5% Female: 55.5%
			EYLEA 2Q4: n= 313		
		96 week study	EYLEA 0.5Q4: n=311 ranibizumab 0.5mg Q4: n=303		

Study Results

Table 13: Efficacy Outcomes at Week 52; VIEW1 and VIEW2 Studies (wet AMD)

Efficacy Outcomes	VIEW1		VIEW2	
	EYLEA 2 mg Q8 ^a	ranibizumab 0.5 mg Q4	EYLEA 2 mg Q8 ^a	ranibizumab 0.5 mg Q4
Per Protocol Set	N=265	N=269	N=270	N=269
Proportion of patients who maintained visual acuity (%) (<15 letters of BCVA loss)	95.1%	94.4%	95.6%	94.4%
Difference ^b (%)	0.7		1.1	
(95% CI) ^c	(-3.1, 4.5) ^d		(-2.6, 4.8) ^d	
Full Analysis Set (FAS)	N=301	N=304	N=306	N=291
Mean number of active injections over 52 weeks	7.6	12.1	7.7	12.7
Mean change in BCVA as measured by ETDRS letter score from Baseline	7.9	8.1	8.9	9.4
Difference ^b in LS mean	0.26		-0.90	
(95% CI) ^c	(-1.97, 2.49)		(-3.06, 1.26)	
Patients who gained at least 15 letters of vision from Baseline (%)	92 (30.6%)	94 (30.9%)	96 (31.4%)	99 (34.0%)
Difference ^b (%)	-0.4		-2.7	
(95% CI) ^c	(-7.7, 7.0)		(-10.2, 4.9)	

BCVA= Best Corrected Visual Acuity; CI= Confidence Interval; ETDRS= Early Treatment Diabetic Retinopathy Study; LOCF= Last Observation Carried Forward (baseline values are not carried forward)

a After treatment initiation with 3 monthly doses

b EYLEA group minus the ranibizumab group.

c 95.1% CI for VIEW1; the CI reflected an alpha adjustment of 0.1% to account for safety assessments of the data by an Independent Data Monitoring Committee

d A confidence interval lying entirely above -10% indicates a non-inferiority of EYLEA to ranibizumab.

52 Week Analyses

In a sensitivity analysis where dropouts were counted as non-responders (regardless of the time of when the dropouts occurred and the patient's visual acuity outcome at the time of dropout), the proportion of patients who maintained visual acuity for the EYLEA 2Q8 arm and ranibizumab 0.5Q4 arm were 88.0% vs. 87.8%, respectively, in VIEW1, and 88.6% vs. 89.4% in VIEW2.


Across both Phase III studies, the EYLEA 2 mg Q8 treatment group received less injections than the ranibizumab 0.5 mg Q4 treatment group (ie, mean [SD] of 7.6 [1.1] injections for EYLEA compared with 12.3 [1.9] injections of ranibizumab).

The proportion of patients who maintained vision in the EYLEA 2mg every 8 weeks treatment arm was shown to be non-inferior to ranibizumab 0.5 mg every 4 weeks.

96 Week Analyses

In the second year, the mean numbers of active injections in VIEW 1 were 4.3 injections in the EYLEA 2Q8 treatment group vs. 4.6 injections in the ranibizumab 0.5Q4 group and in VIEW2, 4.0 injections in the EYLEA 2Q8 group vs. 4.9 injections in the ranibizumab 0.5Q4 group. Ninety percent (90%) of patients originally treated with EYLEA 2Q8 received 6 doses or less and 72% received 4 doses or less among those patients completing the second year of the studies. The proportion of patients who maintained visual acuity was 91.4% in the EYLEA 2Q8 treatment group vs. 89.8% in the ranibizumab 0.5Q4 treatment group in VIEW1, and 93.5% in both treatment groups in VIEW2. The mean change from baseline in BCVA was +7.1 letters in the EYLEA 2Q8 group vs. +7.3 letters in the ranibizumab 0.5Q4 group in VIEW1, and +8.1 letters vs. +8.5 letters in VIEW2. The proportion of patients who gained at least 15 letters of vision from baseline was 32.9% in the EYLEA 2Q8 treatment group vs. 30.6% in the ranibizumab 0.5Q4 treatment group in VIEW1, and 34.0% vs. 32.7% in VIEW2.

Figure 10: Mean Change in Visual Acuity from Baseline to Week 96; Data from the VIEW1 and VIEW2 studies



Treatment of CRVO

Study Demographics and Trial Design

The safety and efficacy of EYLEA (aflibercept) were assessed in two randomized, multi-center, double-masked, sham-controlled studies in patients with macular edema secondary to CRVO. A total of 358 patients were treated and evaluable for efficacy (217 with EYLEA) in the two studies COPERNICUS and GALILEO. (5-10) In both studies, patients were randomly assigned in a 3:2 ratio to either 2 mg EYLEA administered every 4 weeks (2Q4) or the control group receiving sham injections every 4 weeks for a total of 6 injections for the first 24 weeks.

After 6 monthly injections, patients received treatment only if they met pre-specified retreatment criteria, except for patients in the control group in the GALILEO study who continued to receive sham (control to control) (see [Table 13](#)).

The pre-specified retreatment criteria were as follows:

- Greater than 50 micron increase in CRT compared to the lowest previous measurement as assessed by OCT
- New or persistent cystic retinal changes or subretinal fluid as assessed by OCT
- Persistent diffuse edema \geq 250 microns in the central subfield as assessed by OCT
- Loss of five or more letters in BCVA compared to the best previous measurement in conjunction with any increase in CRT as assessed by OCT
- Increase of five or more letters in BCVA compared to the most recent previous assessment.

After 52 weeks, all patients received the treatment if they met pre-specified visual or anatomic retreatment criteria until week 76 (GALILEO study) or week 100 (COPERNICUS study).

In both studies, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters in Best Corrected Visual Acuity (BCVA) at Week 24 compared to baseline. Secondary endpoints included change in visual acuity at Week 24 compared to baseline, the mean change in baseline central retinal thickness, the mean change in the baseline NEI VFQ-25 total score at Week 24 and the proportion of patients progressing to anterior segment neovascularization.

Patient ages ranged from 22 to 89 years with a mean of 64 years. In the CRVO studies, approximately 52% (112/217) of the patients randomized to treatment with EYLEA were 65 years of age or older, and approximately 18% (38/217) were 75 years of age or older.

Table 14 – Summary of Patient Demographics for Clinical Trials in CRVO

Study No.	Trial Design	Dosage, route of administration, and duration	Study Patients (n= number)	Mean Age (Range)	Gender
COPERNICUS	randomized, multi-center, double-masked, sham-controlled	Intravitreal injection	EYLEA: n= 114 Sham: n=74	66.3 (22-89 years)	Male: 57% Female: 43%
		<ul style="list-style-type: none"> EYLEA administered at 2 mg every 4 weeks (EYLEA 2Q4) up to week 24; then EYLEA 2 mg PRN Sham injections every 4 weeks up to week 24; then EYLEA 2 mg PRN 100 week study			
GALILEO		Intravitreal injection	EYLEA: n= 104 Sham: n=68	61.5 (29-88 years)	Male: 55.6% Female: 44.4%
		<ul style="list-style-type: none"> EYLEA administered at 2 mg every 4 weeks (EYLEA 2Q4), up to week 24; then EYLEA 2 mg PRN Sham injections every 4 weeks up to week 52; then EYLEA 2 mg PRN 76 week study			

PRN=*pro re nata* (as needed)

Study Results

Superiority of treatment with EYLEA versus treatment with sham injection was shown for the primary endpoint at 24 weeks in both the COPERNICUS and GALILEO studies. Rapid improvements in visual acuity were observed with EYLEA treatment as early as 4 weeks after the first EYLEA injection.

Results from the analysis of the COPERNICUS and GALILEO studies are shown in [Table 14](#) and [Figure 11](#) below:

Table 15: Efficacy Outcomes at Week 24 (Full Analysis Set with LOCF) in COPERNICUS and GALILEO Studies

Efficacy Outcomes	COPERNICUS		GALILEO	
	EYLEA 2 mg Q4 (N = 114)	Control (Sham) ^a (N = 73)	EYLEA 2 mg Q4 (N = 103)	Control (Sham) ^a (N = 68)
Proportion of patients who gained at least 15 letters in BCVA from baseline ^b	56%	12%	60%	22%
Weighted difference (%) ^{c,d}	44.8%		38.3%	
(95% CI)	(33.0, 56.6)		(24.4, 52.1)	
p-value	p < 0.0001		p < 0.0001	
Mean change in BCVA as measured by ETDRS letter score from baseline (SD)	17.3 (12.8)	-4.0 (18.0)	18.0 (12.2)	3.3 (14.1)
Difference in LS mean ^e	21.7		14.7	
(95% CI)	(17.4, 26.0)		(10.8, 18.7)	
p-value	p<0.0001		p<0.0001	

- a Control group received sham injections every 4 weeks (Q4)
- b Subjects who discontinued prior to week 24 and had less than 5 injections of study drug or sham were evaluated as non-responders; otherwise, missing values were imputed using LOCF analyses in COPERNICUS study. Subjects who discontinued from the study prior to Week 24 were judged as non-responders in GALILEO study.
- c Difference is EYLEA 2 mg Q4 weeks minus control
- d Difference and confidence interval (CI) are calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for region (America vs. rest of the world for COPERNICUS and Europe vs. Asia/Pacific for GALILEO) and baseline BCVA category (> 20/200 and ≤ 20/200)
- e LS mean difference and confidence interval based on an ANCOVA model with factors treatment group, region (America vs. rest of the world for COPERNICUS and Europe vs. Asia/Pacific for GALILEO) and baseline BCVA category (> 20/200 and ≤ 20/200)


BCVA: Best Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; LOCF: Last Observation Carried Forward; SD: Standard deviation; LS: Least square means derived from ANCOVA

In the COPERNICUS study, at Week 52, the proportion of patients gaining at least 15 letters in BCVA from baseline was 55% for the group receiving EYLEA and 30% for the group initially receiving sham treatment, and at Week 100, the proportions were 49.1% and 23.3% for the group receiving EYLEA and for the group initially receiving sham treatment, respectively. At Week 52, the mean improvement from baseline in BCVA was +16.2 letters for the group receiving EYLEA and +3.8 letters for the group initially receiving sham treatment, and at Week 100, the mean improvement were 13.0 and 1.5 letters for the group receiving EYLEA and for the group initially receiving sham treatment, respectively.

At Week 52 in the GALILEO study, the proportion of patients gaining at least 15 letters in BCVA from baseline was 60% for the group receiving EYLEA and 32% for the group initially receiving sham treatment, and at Week 76, the proportions were 57.3% and 29.4% for the group receiving EYLEA and for the group initially receiving sham treatment, respectively. At Week 52, the mean improvement from baseline in BCVA was +16.9 letters for the group receiving EYLEA and +3.8 letters for the group initially receiving sham treatment, and at Week 76, the mean improvement were 13.7 and 6.2 letters for the group receiving EYLEA and for the group initially receiving sham treatment, respectively.

Treatment effects in evaluable subgroups (e.g., age, gender, race, baseline visual acuity, retinal perfusion status, and CRVO duration) in each study were in general consistent with the results in the overall populations.

Figure 11: Mean change from baseline to Week 24 in best corrected visual acuity by treatment group for the COPERNICUS and GALILEO studies (Full Analysis Set, LOCF)



Treatment of BRVO

Study Demographics and Trial Design

The safety and efficacy of EYLEA (aflibercept, solution for intravitreal injection) were assessed in a randomized, multi-center, double-masked, active-controlled study in patients with macular edema secondary to BRVO. (11, 12) A total of 181 patients were treated and evaluable for efficacy (91 with EYLEA) in the VIBRANT study. In the study, patients were randomly assigned in a 1:1 ratio to either 2 mg EYLEA administered every 4 weeks (2Q4) with a total of 6 injections or laser photocoagulation administered at baseline and subsequently as needed at and after week 12 (laser control group) (see Table 15).

After 6 monthly injections (week 24), patients in the EYLEA group received an injection every 2 months (8 weeks) up to week 52. Rescue laser treatment was permitted at week 36 if at least 1 rescue treatment criterion was met:

- >50 micron increase in CRT on OCT compared to the lowest previous measurement
- new or persistent cystic retinal changes or sub-retinal fluid on OCT or persistent diffuse edema in the central subfield on OCT
- a loss of ≥ 5 letters from the best previous measurement due to BRVO, in conjunction with any increase in retinal thickness in the central subfield on OCT from the best previous measurement.

For patients randomized to the laser control group, additional rescue laser treatment and rescue treatment with EYLEA starting at week 24 (3 monthly injections followed by an injection every 2 months) were also permitted if specific criteria (above) were met.

9 of 91 patients in the EYLEA group received laser therapy at week 36 and 67 of 90 patients in the laser group received EYLEA treatment after week 24.

Patient ages ranged from 42 to 94 years with a mean of 65 years. At baseline, 22% (20/91) of the patients randomized to treatment with EYLEA had a retinal perfusion status classified as non-perfused. 19.8% patients in the EYLEA group and 16.3% of patients in the laser + EYLEA group discontinued the study prior to week 52.

In the VIBRANT study, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters in BCVA at Week 24 compared to baseline. Secondary endpoints efficacy analyses included change from baseline in BCVA score and change from baseline in CRT.

Table 16 – Summary of Patient Demographics for Clinical Trial in BRVO

Study No.	Trial Design	Dosage, route of administration, and duration	Study Patients (n= number)	Mean Age (Range)	Gender
VIBRANT	randomized, multi-center, double-masked, active-controlled	Intravitreal injection <ul style="list-style-type: none"> EYLEA administered at 2 mg every 4 weeks (EYLEA 2Q4) up to week 24; then EYLEA 2 mg every 8 weeks (EYLEA 2Q8). Rescue laser treatment was permitted at week 36 if rescue treatment criteria were met. Laser treatment at day 1 and sham injections every 4 weeks up to week 48 Rescue treatment with EYLEA starting at week 24 was permitted if rescue treatment criteria were met. 52 week study	EYLEA: n= 91 Sham: n=92	65.5 (42-94 years)	Male: 54.1% Female: 45.9%

Study Results

At week 24, the results of patients in the EYLEA group were shown superior to the laser control for the primary endpoint (the proportion of patients who gained at least 15 letters in BCVA at week 24) and secondary endpoints of visual acuity (mean change from baseline in BCVA at week 24). A rapid gain in visual acuity was observed as early as one week after treatment initiation with EYLEA.

Results from the analysis of the VIBRANT study are shown in [Table 16](#) and [Figure 12](#) below:

Table 17: Efficacy Outcomes at Week 24 (Full Analysis Set with LOCF) in BRVO (VIBRANT study)

Efficacy Outcomes	Week 24	
	EYLEA 2 mg Q4 (N = 91)	Control (Laser) ^a (N = 90)
Proportion of patients who gained at least 15 letters in BCVA from baseline	52.7%	26.7%
Adjusted difference (%) ^{b,c}	26.6%	
(95% CI)	(13.0, 40.1)	
p-value ^d	p= 0.0003	
Mean change in BCVA as measured by ETDRS letter score from baseline (SD)	17.0 (11.9)	6.9 (12.9)
Difference in LS mean ^{b,e}	10.5	
(95% CI)	(7.1, 14.0)	
p-value ^e	p< 0.0001	

a Control group received sham injections every 4 weeks (Q4)

b Difference is EYLEA 2 mg Q4 weeks minus laser group

c Difference and confidence interval (CI) were calculated using Mantel-Haenszel weighting scheme adjusted by regions (Japan vs North America) and baseline Best Corrected Visual Acuity (BCVA) (BCVA ≤20/200 and BCVA >20/200).

d P-value was calculated using 2-sided Cochran-Mantel-Haenszel test adjusted by regions (Japan vs North America) and baseline BCVA (BCVA ≤20/200 and BCVA >20/200).


e LS mean difference and confidence interval (CI) and p-value were based on an analysis of covariance (ANCOVA) model with baseline measurement as covariate and treatment group, region, and baseline Best Corrected Visual Acuity (BCVA) (BCVA ≤20/200 and BCVA >20/200) as fixed factors.

BCVA: Best Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; LOCF: Last Observation Carried Forward; SD: Standard deviation; LS: Least square means derived from ANCOVA

In the VIBRANT study, at week 52, the proportion of patients gaining at least 15 letters in BCVA from baseline was 57.1% for the group receiving EYLEA and 41.1% for the group initially receiving laser treatment. At week 52, the mean improvement from baseline in BCVA was +17.1 letters for the group receiving EYLEA and +12.2 letters for the group initially receiving laser treatment. At week 52, the mean change in CRT was -284 microns for the group receiving EYLEA and -249 microns for the group initially receiving laser treatment.

Treatment effects in evaluable subgroups (e.g., age, gender, and baseline retinal perfusion status) in the study were in general consistent with the results in the overall populations.

Figure 12: Change From Baseline to Week 24 in Mean BCVA Score in BRVO (VIBRANT study) (LOCF) (Full Analysis Set)



Treatment of DME

Study Demographics and Trial Design

The safety and efficacy of EYLEA were assessed in two randomized, multi-center, double-blind, active-controlled studies in patients with DME (VIVID^{DME} and VISTA^{DME}). (13) The VIVID^{DME} study was conducted in Europe, Australia and Japan and the VISTA^{DME} study was conducted in the US. A total of 862 randomized and treated patients were evaluable for efficacy. Of those, 576 were randomized to the EYLEA groups in the two studies. In each study, patients were randomly assigned in a 1:1:1 ratio to 1 of 3 treatment regimens:

- 1) EYLEA administered 2 mg every 8 weeks following 5 initial monthly injections (EYLEA 2Q8);
- 2) EYLEA administered 2 mg every 4 weeks (EYLEA 2Q4); and
- 3) Macular laser photocoagulation (active control laser).

Beginning at week 24, patients meeting a pre-specified threshold of vision loss were eligible to receive additional treatment: patients in the EYLEA groups could receive laser and patients in the control (laser) group could receive EYLEA.

In both studies, the primary efficacy endpoint was the mean change from baseline in BCVA at Week 52 as measured by ETDRS letter score. The key secondary efficacy endpoints included proportion of patients who gained ≥ 10 or ≥ 15 ETDRS letters from baseline to week 52, the proportion of patients who achieved a ≥ 2 step improvement in the ETDRS Diabetic Retinopathy Severity Score (DRSS), and the mean change from baseline in CRT.

Patient ages ranged from 23 to 87 years with a mean of 63 years. In the DME Phase III studies, approximately 47% (268/576) of the patients randomized to treatment with EYLEA were 65 years of age or older, and approximately 9% (52/576) were 75 years of age or older.

Overall, half of the patients in the VIVID^{DME} and VISTA^{DME} studies had poorly controlled diabetes at baseline.

In the VIVID^{DME} study, the mean numbers of injections in the 2Q8 and 2Q4 groups were 8.7 and 12.2, respectively, and the mean numbers of laser treatments in the laser group was 2.1. In the VISTA^{DME} study, the mean numbers of injections in the 2Q8 and 2Q4 groups were 8.4 and 11.8, respectively, and the mean number of laser treatments in the laser group was 2.7.

In the VIVID^{DME} and VISTA^{DME} studies, 36 (8.9%) and 197 (42.9%) of the patients received prior anti-VEGF therapy, respectively, with a 3-month or longer washout period. Treatment effects in the subgroup of patients who had previously been treated with a VEGF inhibitor prior to study participation were similar to those seen in patients who were VEGF inhibitor naïve prior to study participation.

More than 80% of patients in all treatment groups in VIVID^{DME} and VISTA^{DME} had a DRSS at baseline of mild to severe non-proliferative diabetic retinopathy.

In the VISTA^{DME} study, >60% of patients in the EYLEA groups received bilateral EYLEA injections.

Study Results

In both VIVID^{DME} and VISTA^{DME} studies, the 52-week results demonstrate statistically significant superiority of EYLEA 2Q8 and 2Q4 treatment groups as compared to laser control on both primary and secondary endpoints.

A rapid improvement in BCVA was observed as early as one week in the EYLEA-treated patients. In the VIVID^{DME} study, the mean change in BCVA after the initial 4 week period was a gain of +5.4 (2Q8), +5.7 (2Q4) and +0.9 (laser) letters. In the VISTA^{DME} study, the mean change in BCVA after the initial 4 week period was a gain of +6.6 (2Q8), +7.0 (2Q4) and +2.6 (laser) letters.

Detailed results from the analysis of the VIVID^{DME} and VISTA^{DME} studies are shown in [Table 17](#) and [Figure 13](#) below.

Table 18: Efficacy Outcomes at Week 52 (Full Analysis Set with LOCF) in VIVID^{DME} and VISTA^{DME} Studies

Efficacy Outcomes	VIVID ^{DME} 52 Weeks			VISTA ^{DME} 52 Weeks		
	EYLEA 2Q8 ^a (n = 135)	EYLEA 2Q4 (n = 136)	Control (laser) (n = 132)	EYLEA 2Q8 ^a (n = 151)	EYLEA 2Q4 (n = 154)	Control (laser) (n = 154)
Mean change in BCVA as measured by ETDRS letter score from Baseline (SD)	10.7 (9.32)	10.5 (9.55)	1.2 (10.65)	10.7 (8.21)	12.5 (9.54)	0.2 (12.53)
Difference in LS mean ^{b, c} (97.5% CI)	9.1 (6.3, 11.8)	9.3 (6.5, 12.0)		10.45 (7.73, 13.17)	12.19 (9.35, 15.04)	
p-value	p < 0.0001	p < 0.0001		p < 0.0001	p < 0.0001	
Proportion of patients who gained at least 15 letters in BCVA from Baseline	33.3%	32.4%	9.1%	31.1%	41.6%	7.8%
Adjusted Difference ^{c, d} (97.5% CI)	24.2% (13.5, 34.9)	23.3% (12.6, 33.9)		23.3% (13.5, 33.1)	34.2% (24.1, 44.4)	
p-value	p < 0.0001	p < 0.0001		p < 0.0001	p < 0.0001	

a After treatment initiation with 5 monthly injections

b LS mean and CI based on an ANCOVA model with baseline BCVA measurement as a covariate and a factor for treatment group. Additionally, region (Europe/Australia vs. Japan) had been included as a factor for VIVID^{DME}, and history of MI and/or CVA as a factor for VISTA^{DME}.

c Difference is EYLEA group minus active control (laser) group

d Difference with confidence interval (CI) and statistical test is calculated using Mantel-Haenszel weighting scheme adjusted by region (Europe/Australia vs. Japan) for VIVID^{DME} and medical history of MI or CVA for VISTA^{DME}


BCVA: Best Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; LOCF: Last Observation Carried Forward; SD: Standard deviation; LS: Least square means derived from ANCOVA; CI: Confidence interval; MI: Myocardial Infarction; CVA: cerebrovascular accident

In the VIVID^{DME} study, at Week 52, the proportion of patients gaining ≥ 10 letters in BCVA from baseline was 53.3%, 54.4% and 25.8% for the groups receiving EYLEA 2Q8, EYLEA 2Q4, and control (laser), respectively. In the VISTA^{DME} study, the corresponding results at Week 52 were 58.3%, 64.9% and 19.5%, respectively.

The proportion of patients with improvement of ≥ 2 steps on the ETDRS DRSS from baseline was 27.7%, 33.3% and 7.5% for the groups receiving EYLEA 2Q8, EYLEA 2Q4, and control (laser), respectively, at Week 52 in the VIVID^{DME} study. In the VISTA^{DME} study, the corresponding results at Week 52 were 29.1%, 33.8% and 14.3%, respectively.

At Week 52, the mean change from baseline in CRT in the VIVID^{DME} study was -192.4 microns, -195 microns, and -66.2 microns for the group receiving EYLEA 2Q8, EYLEA 2Q4, and control (laser), respectively. In the VISTA^{DME} study, the corresponding results at Week 52 were -183.1 microns, -185.9 microns, and -73.3 microns, respectively.

Figure 13: Mean change in BCVA as Measured ETDRS Letter Score from Baseline to Week 52 in VIVID^{DME} and VISTA^{DME} Studies



Treatment effects in evaluable subgroups (e.g., age, gender, race, baseline HbA1c, baseline visual acuity, prior anti-VEGF therapy) in each study and in the combined analysis were consistent with the results in the overall populations.

Treatment of myopic CNV

Study Demographics and Trial Design

The safety and efficacy of EYLEA in subjects with choroidal neovascularization secondary to pathologic myopia (myopic CNV) were assessed in a randomized, parallel-group, multi-center, double-masked, sham-controlled Phase 3 study conducted in Japan, Hong Kong, Singapore, Taiwan and South Korea. (14)

122 subjects (91 EYLEA and 31 Sham) were randomized 3:1 to the EYLEA or Sham groups. Patients randomized to the EYLEA group received 1 injection at baseline. Additional injections

were performed in case of CNV persistence or recurrence at monthly visits through week 44. Patients randomized to the Sham group received a sham injection at baseline. Although subjects randomized to the Sham group underwent assessment of re-treatment criteria for masking purposes, an injection of active drug was not given regardless of the outcome of this assessment. Patients were evaluated at 4-week intervals for BCVA using the ETDRS chart at 4 meters. At week 24, after assessment of the primary efficacy end point, patients in the Sham group received a mandatory EYLEA injection followed by EYLEA (if disease persisted/recurred) or sham injection every 4 weeks.

A total of 14 subjects discontinued the study treatment prior to Week 24; 8 (8.8%) in the EYLEA group and 6 (19.4%) in the Sham group. Between Week 24 and Week 48, treatment was discontinued in 5 subjects (5.5%) in the EYLEA group and in one subject (3.2%) in the Sham+EYLEA group.

The majority of patients were female (76.0%) and Japanese (74.4%), and the mean age was 58.2 years (range 27-83). Most patients had classic CNV (98.3%) and a disease duration of <2 months (80.2%). The mean axial length was 28.7 (SD 1.6) mm. Approximately 97% of patients had a baseline BCVA of >20/200 (≥ 35 letters) and, in both groups, the mean baseline BCVA letter score was approximately 56.5 letters.

Overall, patients in the EYLEA group received a median of 3.0 (range 1-12) injections over the study period of 48 weeks.

The primary efficacy endpoint was the mean change in visual acuity at week 24 compared to baseline.

The confirmatory secondary efficacy endpoint was the proportion of patients who gained at least 15 letters in BCVA at week 24 compared to baseline.

Study Results

In the MYRROR study, the 24-weeks results demonstrated statistical superiority of EYLEA as compared to sham injections on both primary and confirmatory secondary endpoints ([Table 19](#)). In the EYLEA group, the mean change in BCVA was maintained until Week 48 ([Figure 14](#)).

Table 19: Efficacy Outcomes at Week 24 (primary analysis) in MYRROR study (Full Analysis Set with LOCF)

Efficacy Outcomes	24 Weeks	
	EYLEA 2mg (N = 90)	Sham (N = 31)
Mean change in BCVA letter score as measured by ETDRS from baseline (SD)	12.1 (8.3)	-2.0 (9.7)
Difference in LS mean ^{a,b}	14.1	
(95% CI)	(10.8, 17.4)	
p-value ^d	p < 0.0001	
Proportion of patients who gained at least 15 letters in BCVA from baseline	38.9%	9.7%
Weighted difference ^{a,c}	29.2%	
(95% CI)	(14.4, 44.0)	
p-value ^d	p = 0.0001	

^a Difference is EYLEA 2mg minus sham at Week 24.

^b LS mean difference and 95% CI based on an ANCOVA model with treatment group and country (country designations) as fixed effects, and baseline BCVA as covariant.


^c Difference and 95% CI are calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for country (country designations)

^d To control the type I error rate for multiple testing, the confirmatory secondary endpoint was only tested if the null hypothesis for the primary endpoint could be rejected

LOCF: Last Observation Carried Forward; BCVA: Best Corrected Visual Acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; SD: Standard Deviation; LS mean: Least square means; CI: Confidence Interval

At week 48, the mean improvement from baseline in BCVA was +13.5 letters for the group receiving EYLEA and +3.9 letters for the Sham+EYLEA group. At week 48, the proportion of patients gaining at least 15 letters in BCVA from baseline was 50.0% for the group receiving EYLEA and 29.0% for the group initially receiving sham injections.

Figure 14: Mean change from baseline to week 48 in visual acuity by treatment group for the MYRROR study (Full Analysis Set, LOCF)



DETAILED PHARMACOLOGY

Animal Pharmacology

In animal studies, aflibercept can reduce pathological neovascularization and associated vascular leakage in a number of different models of ocular disease. (15, 16) For example, intravitreal administration of aflibercept to monkeys reduced the development of significant choroidal neovascularization (CNV) following laser injury, and reduced leakage from retinal vessels in the diabetic rat model and blocked abnormal vessel formation in the mouse hyperoxia model, compared to control animals.

Human Pharmacology

Hepatic Insufficiency

No specific studies in patients with hepatic impairment were conducted with EYLEA.

TOXICOLOGY

Erosions and ulcerations of the respiratory epithelium in nasal turbinates in monkeys treated with aflibercept were observed at intravitreal doses of 2 or 4 mg/eye. At the NOAEL of 0.5 mg per eye in monkeys, the systemic exposure (AUC) was 56 times higher than the exposure observed in humans after an intravitreal dose of 2 mg. Similar effects were not seen in clinical studies.

Repeated Dose Toxicity

Effects in nonclinical studies on repeated dose toxicity were observed only at systemic exposures considered substantially in excess of the maximum human exposure after intravitreal administration at the intended clinical dose indicating little relevance to clinical use.

Carcinogenicity

No studies have been conducted on the carcinogenic potential of aflibercept.

Reproductive Toxicology

Effects on male and female fertility were assessed as part of a 6-month study in monkeys with intravenous administration of aflibercept at weekly doses ranging from 3 to 30 mg/kg. Absent or irregular menses associated with alterations in female reproductive hormone levels and changes in sperm morphology and motility were observed at all dose levels. In addition, females showed decreased ovarian and uterine weight accompanied by compromised luteal development and reduction of maturing follicles. These changes correlated with uterine and vaginal atrophy. A No Observed Adverse Effect Level (NOAEL) was not identified. Intravenous administration of the lowest dose of aflibercept assessed in monkeys (3 mg/kg) resulted in systemic exposure (AUC) that was approximately 1500-fold higher than the exposure observed in humans after an intravitreal dose of 2 mg. All changes were reversible within 20 weeks after cessation of treatment.

Aflibercept produced embryo-fetal toxicity in an embryo-fetal development study in pregnant rabbits with intravenous administration (3 to 60 mg/kg). The maternal NOAEL was at the dose of 3 mg/kg. At this dose, the systemic exposures based on C_{max} and AUC for free aflibercept were approximately 2000- and 600-fold higher, respectively, when compared to corresponding values observed in humans after an intravitreal dose of 2 mg.

In an embryo-fetal development study in pregnant rabbits, aflibercept produced embryo-fetal toxicity when administered every three days during organogenesis to pregnant rabbits at intravenous doses ≥ 3 mg per kg (3 to 60 mg/kg), or every six days at subcutaneous doses ≥ 0.1 mg per kg. Adverse embryo-fetal effects included increased incidences of postimplantation loss and fetal malformations, including anasarca, umbilical hernia, diaphragmatic hernia, gastroschisis, cleft palate, ectrodactyly, intestinal atresia, spina bifida, encephalomeningocele, heart and major vessel defects, and skeletal malformations (fused vertebrae, sternebrae, and ribs; supernumerary vertebral arches and ribs; and incomplete ossification). The maternal No Observed Adverse Effect Level (NOAEL) in these studies was 3 mg per kg. Aflibercept produced fetal malformations at all doses assessed in rabbits and the fetal NOAEL was less than 0.1 mg per kg. Administration of the lowest dose assessed in rabbits (0.1 mg per kg) resulted in systemic exposure (AUC) that was approximately 10 times the systemic exposure observed in humans after a single intravitreal dose of 2 mg.

Mutagenesis

No studies have been conducted on the mutagenic potential of aflibercept.

REFERENCES

1. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. *Proc Natl Acad Sci U S A*. 2002;99(17):11393-8.
2. Rudge JS, Holash J, Hylton D, Russell M, Jiang S, Leidich R, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. *Proc Natl Acad Sci U S A*. 2007;104(47):18363-70.
3. Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development. *Curr Opin Drug Discov Devel*. 2007;10(1):84-96.
4. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. *Ophthalmology*. 2012;119(12):2537-48.
5. Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. *Br J Ophthalmol*. 2013;97(3):278-84.
6. Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. *Ophthalmology*. 2012;119(5):1024-32.
7. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. *Am J Ophthalmol*. 2013;155(3):429-37 e7.
8. Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, et al. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. *Ophthalmology*. 2014;121(1):202-8.
9. Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, et al. Intravitreal Aflibercept Injection for Macular Edema Due to Central Retinal Vein Occlusion: Two-Year Results from the COPERNICUS Study. *Ophthalmology*. 2014.
10. Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. *Am J Ophthalmol*. 2014;158(5):1032-8.
11. Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: The 24-Week Results of the VIBRANT Study. *Ophthalmology*. 2014.
12. Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. *Ophthalmology*. 2015.

13. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal Aflibercept for Diabetic Macular Edema. *Ophthalmology*. 2014.
14. Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T, et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. *Ophthalmology*. 2015;122(6):1220-7.
15. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. *J Clin Invest*. 2004;113(7):1040-50.
16. Cao J, Zhao L, Li Y, Liu Y, Xiao W, Song Y, et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. *Invest Ophthalmol Vis Sci*.51(11):6009-17.

PART III: CONSUMER INFORMATION

PrEYLEA®

Aflibercept, solution for intravitreal injection

This leaflet is Part 3 of a three-part "Product Monograph" published when EYLEA was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about EYLEA. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:

EYLEA ("I-LEE-ah") is a solution which is injected into the eye (intravitreal injection) by your doctor with local anesthesia (freezing) to treat the eye conditions neovascular (wet) age-related macular degeneration – (wet) AMD, macular edema secondary to central retinal vein occlusion (CRVO), macular edema secondary to branch retinal vein occlusion (BRVO), diabetic macular edema (DME) or myopic choroidal neovascularization (mCNV). There is no clinical trial experience with EYLEA in the treatment of non-Asian patients with myopic CNV.

What it does:

Growth factors (known as VEGF-A and PIGF) can cause extra blood vessels to grow and leak in the back of the eye, which can cause loss of vision.

Vascular Endothelial Growth Factor (VEGF) and Placental Growth Factor (PIGF) are proteins that play an important role in making the abnormal blood vessels that contribute to the progression of wet AMD and the macular edema (swelling) that is seen with diabetic macular edema (DME). These blood vessels are fragile and can leak fluid and blood into the macula, leading to vision loss. DME is a swelling of the retina occurring in patients with diabetes due to leaking of fluid from blood vessels within the macula. The macula is the portion of retina responsible for fine vision. When the macula swells with fluid, central vision becomes blurry.

In Central Retinal Vein Occlusion (CRVO), a blockage occurs in the main blood vessel that transports blood away from the retina (the light sensitive back part of the eye), where fluid accumulates in the back of the eye, causing swelling (called macular edema).

In patients with BRVO, one or more branches of the main blood vessel that transports blood away from the retina is blocked, which cause the fluid accumulation in the back of the eye (swelling, called macular edema).

Myopic choroidal neovascularization (mCNV) is a severe form of myopia (near sightedness) which leads to elongated eyes with additional defects such as thinning, cracks and ruptures in some of the layers in the back of the eye. This triggers the abnormal formation of new blood vessels which can cause bleeding into the eye and eventually may lead to loss of vision.

Aflibercept, the active substance in EYLEA, blocks these growth factors, and has been shown to help improve vision or slow vision loss from wet AMD, CRVO, BRVO, DME, and myopic CNV.

These diseases may cause decreased vision.

EYLEA has been shown to slow down the progression of vision loss, improve vision, as well as the ability to perform related activities (e.g. reading, driving, etc.).

When it should not be used:

EYLEA must not be used if you:

- are allergic (hypersensitive) to aflibercept or any of the other ingredients of EYLEA listed below
- have inflammation of the eye (symptoms include eye pain, redness and trouble seeing)
- have an infection in or around the eye (ocular or periocular infection)

What the medicinal ingredient is:

The active substance in EYLEA is aflibercept.

What the nonmedicinal ingredients are:

The other inactive ingredients are: sodium phosphate, monobasic, monohydrate; sodium phosphate, dibasic, heptahydrate; sodium chloride; sucrose; polysorbate 20; and water for injection.

What dosage forms it comes in:

EYLEA is a sterile, clear, colourless to pale yellow, solution for injection which is iso-osmotic (similar properties to the inside of your eye). EYLEA is supplied as a single dose pack in a vial for the treatment of one eye.

Vials:

Each carton includes a single-dose glass vial containing a fill volume of 278 microliters solution for injection with a rubber stopper, and an 18 gauge filter needle.

WARNINGS AND PRECAUTIONS

Take special care with EYLEA:

- Injection with EYLEA may trigger an increase in eye pressure (intraocular pressure) in some patients within 60 minutes of the injection. Your doctor may monitor this after each injection. If you have glaucoma (increased eye pressure), please tell your doctor.
- Although uncommon, all intravitreal injections, including those with EYLEA, carry a risk of serious infection or inflammation inside the eye (endophthalmitis), detachment or tear of the retina at the back of the eye (symptoms include eye pain, worsening eye redness, blurred or decreased vision, sensitivity to light, sudden loss of vision, flashing lights and black spots), and cataracts (clouding of the lens in

the front of the eye). Please contact your doctor immediately if you develop any of these symptoms.

- Inform your doctor if you have already had a stroke or experienced transient signs of stroke (weakness or paralysis of limbs or face, difficulty speaking or understanding). This information will be taken into account to evaluate if EYLEA is the appropriate treatment for you.

Before you use EYLEA, talk to your doctor or pharmacist if:

- **You are taking other medicines:** Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
- **You are or plan to become pregnant:** There is no experience of using EYLEA in pregnant women. In animals, high doses have been shown to have toxic effects on the fetus. Therefore, EYLEA is not recommended during pregnancy unless the potential benefit outweighs the potential risk to the fetus. If you are pregnant or planning to become pregnant, discuss this with your doctor before treatment with EYLEA. Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of EYLEA.
- **You are breast-feeding:** EYLEA is not recommended during breast-feeding as it is not known whether aflibercept passes into human milk. A risk to the breast-fed child cannot be excluded. Ask your doctor for advice before starting EYLEA treatment. A decision must be made whether to discontinue breast-feeding or to abstain from EYLEA therapy.
- You have a history of seeing flashes of light or floaters, or if you have a sudden increase in the size or number of floaters.

The use of EYLEA in children and adolescents has not been studied and is therefore not recommended

Driving and Using Machines

After your EYLEA injection, you may experience some temporary visual disturbances. Do not drive or use machinery as long as these last.

PROPER USE OF THIS MEDICATION

Usual dose

EYLEA is intended for injection into the eye. It must only be administered by a doctor experienced in giving eye injections.

EYLEA will be injected under aseptic (clean and sterile) conditions. Before the injection, your doctor will use a disinfectant eyewash to clean your eye carefully to prevent infection. Your doctor will also give you a local anesthetic to reduce or prevent any pain you might have with the injection.

Treatment of AMD

The recommended dose of EYLEA is 2 mg (0.05 mL or 50 microliters). It will be administered once a month (every 4 weeks) for the first 3 months then you may receive an injection every 2 months

(8 weeks) for the first 12 months of treatment. After the first 12 months of treatment, EYLEA may be administered up to every 3 months (12 weeks) based on your doctor's assessment. The interval between two doses should not be shorter than one month. Your doctor will monitor your vision regularly.

Treatment of CRVO and BRVO

The recommended dose of EYLEA is 2 mg (0.05 mL or 50 microliters). EYLEA will be administered once every month (4 weeks) and may be extended to up to every 3 months (12 weeks) based on examination by your doctor. The interval between two doses should not be shorter than one month. Your vision will be monitored by your doctor every 1 to 2 months to determine the need for continued treatment.

Treatment of DME

If you are a patient with diabetic macular edema, the recommended dose of EYLEA is 2 mg (0.05 mL or 50 microliters). You will be treated with EYLEA once a month (every 4 weeks) for the first 5 consecutive months, then you may receive one injection every 2 months (8 weeks) thereafter. Unless you experience any problems or are advised differently by your doctor, there is no need for you to see your doctor in between the injections.

Your doctor may decide to treat you with EYLEA as frequently as every month.

Treatment of myopic CNV

If you are a patient with myopic choroidal neovascularization you will be treated with one single injection of EYLEA 2 mg (0.05 mL or 50 microliters) at the beginning of your therapy. You will receive additional injections only if during examination your doctor finds that your disease persists. If your disease resolves, your treatment will stop. In case your disease recurs it will be treated like a new disease.

The interval between two doses should not be shorter than one month.

Use in children: Wet AMD does not occur in children or adolescents. Therefore, the safety and efficacy of EYLEA have not been studied in this age group.

The safety and efficacy of EYLEA have not been studied in patients who are younger than 18 years of age with CRVO, BRVO, DME, and myopic CNV.

If you missed your appointment

If a dose of EYLEA is missed, make a new appointment for an examination and injection.

Before stopping EYLEA treatment

Consult your doctor before stopping the treatment. If you have any further questions about the use of this product, ask your doctor.

Overdosage

For management of a suspected drug overdose, contact your regional Poison Control Centre.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medicines, EYLEA can cause side effects, although not everybody gets them.

With administration of EYLEA, there may be some side effects due to the injection procedure. Some of these may be serious and include infection or inflammation inside the eye (endophthalmitis), sudden loss or change of sharpness of vision (detachment or tear of retina), increase of pressure inside the eye (intraocular pressure), clouding of the lens due to injury (cataract traumatic), and detachment of the gel-like substance inside the eye from the retina (vitreous detachment), in AMD clinical studies; endophthalmitis, cataract and vitreous detachment in CRVO clinical studies; cataract in BRVO clinical studies; retinal detachment in DME clinical studies; and macular hole in the myopic CNV clinical study. These serious side effects occurred in less than 1 in 1000 (16 of 26,780 injections in AMD studies; 3 out of 2,728 intravitreal injections in CRVO clinical studies; 1 out of 1,115 intravitreal injections in BRVO clinical studies; 1 out of 5940 intravitreal injections in DME clinical studies; and 1 out of 474 injections in the myopic CNV study.

The following is a list of the side effects reported to be possibly related to the injection procedure or to the medicine. Please do not get alarmed, you might not experience any of these. Always discuss any suspected side effects with your doctor.

Very common side effects (more than 1 in 10 patients may be affected):

- bloodshot eye caused by bleeding from small blood vessels in the outer layers of the eye (conjunctival hemorrhage)

Common side effects (between 1 and 10 in every 100 patients may be affected):

- decreased sharpness of vision (retinal pigment epithelium tear*, detachment of the retinal pigment epithelium)*
- certain forms of clouding of the lens (cataract, cataract nuclear, cataract subcapsular)
- damage to the front layer of the eyeball (corneal erosion, corneal abrasion, punctate keratitis)
- increase in eye pressure (intraocular pressure increased)
- blurred vision
- moving spots in vision (vitreous floaters)
- detachment of the vitreous (gel-like substance inside the eye) from the retina (vitreous detachment)
- a feeling of having something in the eye (foreign body sensation in eyes)
- increased tear production (lacrimation increased)
- swelling of the eyelid (eyelid edema)
- eye pain

- pain or bleeding at the injection site (injection site pain or hemorrhage)
- redness of the eye (conjunctival hyperemia, ocular hyperemia)

*) Conditions known to be associated with wet AMD; observed in wet AMD patients only.

Uncommon side effects (between 1 and 10 in every 1,000 patients may be affected):

- abnormal sensation in the eye
- infection or inflammation inside the eye (endophthalmitis)
- irritation at the injection site
- irritation of the eyelid
- decreased sharpness of vision (retinal detachment, retinal tear)
- generalized allergic reactions (hypersensitivity)**
- inflammation of certain parts of the eye (iritis, anterior chamber flare)
- certain forms of clouding of the lens (cataract cortical, lenticular opacities)
- damage of the front layer of the eyeball (corneal epithelium defect)
- swelling of the front layer of the eyeball (corneal edema)
- inflammation in the iris of the eye (iritis)

** Allergic reactions like rash, itching (pruritus), hives (urticaria), and a few cases of severe allergy (anaphylactic/anaphylactoid) reactions were reported

Rare side effects (between 1 and 10 in every 10,000 patients may be affected):

- inflammation of certain parts of the eye (uveitis, vitritis)
- pus in front of the iris (coloured part of the eye) (hypopyon)
- clouding of the lens due to injury (cataract traumatic)

The use of VEGF inhibitors similar to those contained in EYLEA, but which have an effect throughout the body (systemic effect) is potentially related to risk of arterial thromboembolic events (of blood clots blocking blood vessels) which may lead to heart attack or stroke. There is a theoretical risk of such events following injection of EYLEA into the eye.

As with all therapeutic proteins, EYLEA may cause an immune reaction (formation of antibodies).

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom/ Effect		Talk with your doctor or pharmacist	
		Only if severe	In all cases
Common (between 1 and 10 in every 100 patients may be affected)	Detachment of the outer layer of the retina (symptoms can include sudden appearance of floaters, flashes of light or a shadow over a portion of the visual field)		✓
	Clouding of vision		✓
	Damage to the cornea (the front layer of the eyeball) (symptoms can include eye pain, blurred vision, tearing, redness and extreme sensitivity to light)		✓
	Visual disturbances caused by detachment of the inner layer of the eye (sudden loss of vision, flashing lights, black spots)		✓
	Signs of stroke, such as weakness or paralysis of limbs or face, trouble speaking or understanding, sudden blurring or loss of vision: seek emergency medical care immediately*		✓
Uncommon (between 1 and 10 in every 1,000 patients may be affected)	Infection or inflammation inside the eye (symptoms can include eye pain, swelling around the eye, light sensitivity, and worsening of vision) (endophthalmitis)		✓
	Increased pressure in the eye		✓
	Shock (Hypersensitivity) – fast pulse, low blood pressure, sweating)		✓
	Disturbed or blurred vision (retinal tear)		✓
	A sudden increase in new moving spots in vision and flashes of light in your side vision (vitreous detachment)		✓
	A feeling that you have something in your eye, a teary red eye, blurred vision in one eye, headache or unusual sensitivity to light (corneal abrasion)		✓

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom/ Effect		Talk with your doctor or pharmacist	
		Only if severe	In all cases
Rare (between 1 and 10 in every 10,000 patients may be affected)	Hypopyon (pus in the eye)		✓
	Macular hole (symptoms can include distortion or blurriness in straight-ahead vision, straight lines or objects begin to look bent or wavy)		✓
* There is a theoretical risk of ATEs, including stroke, following injection of EYLEA into the eye.			

This is not a complete list of side effects. For any unexpected effects while taking EYLEA, contact your doctor or pharmacist.

HOW TO STORE IT

- Keep EYLEA out of the reach and sight of children.
- Store in a refrigerator (2°C to 8°C). Do not freeze.
- Prior to usage, the unopened vial may be stored at room temperature (25°C) for up to 24 hours
- Keep the vial in its outer carton in order to protect from light.

REPORTING SUSPECTED SIDE EFFECTS

To monitor drug safety, Health Canada through the Canada Vigilance Program collects information on serious and unexpected side effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Canada Vigilance:

REPORTING SUSPECTED SIDE EFFECTSCanada Vigilance Program:

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
 - Fax toll-free to 1-866-678-6789, or
 - Mail to:
 - Canada Vigilance Program
 - Health Canada
 - Postal Locator 1908C
 - Ottawa, Ontario
 - K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Website at www.healthcanada.gc.ca/medeffect.

Note: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

For more information, please contact your health professional or pharmacist first, or Bayer Medical Information at 1-800-265-7382 or canada.medinfo@bayer.com.

This document plus the full product monograph, prepared for health professionals can be found at: <http://www.bayer.ca> or by contacting the manufacturer, at the above-mentioned phone number and e-mail address.

This leaflet was prepared by:



Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
Canada

Last revised: May 19, 2017

© 2017, Bayer Inc.

® see www.bayer.ca/tm-mc